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Abstract

EXAMINATION OF THE DISCRIMINATIVE STIMULUS AND CROSSTOLERANCE INDUCING PROPERTIES OF N-DESMETHYLCLOZAPINE IN
C57BL/6 MICE.

By Jason Wiebelhaus
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Joseph H. Porter
Professor, Department of Psychology

Due to its unique receptor binding profile and its relationship to clozapine, Ndesmethylclozapine (NDMC) has been examined as a possible antipsychotic drug (APD).
Clozapine has been trained as discriminative stimulus in our lab, but NDMC has not yet
been established as a discriminative stimulus. In experiment 1, 12 C57BL/6 mice were
trained to discriminate 10.0 mg/kg NDMC from VEH using a standard-two lever operant
procedure to assess antipsychotic substitution. The typical APD clozapine fully substituted
for NDMC at 2 doses tested (2.5 and 5.0 mg/kg), while typical APD haloperidol failed to
substitute for NDMC. In Experiment 2, 11 mice were given repeated administration of

vii

NDMC to assess cross-tolerance development to the discriminative stimulus of clozapine.
NDMC was successfully trained as a discriminative stimulus and was also shown to induce
cross-tolerance to clozapine’s discriminative stimulus, indicating similar underlying
pharmacological mechanisms of action between NDMC and clozapine.

viii

Introduction
Schizophrenia
Schizophrenia is a devastating neurological disorder that affects roughly .07% of
the world’s population (Saha, Chant, Welham, & McGrath, 2005). It is a complicated
disorder that affects many people indiscriminant of gender, culture, and social class, and
commonly begins during early adulthood. Schizophrenia is a difficult prognosis to endure,
having a mortality rate two to three times higher than the average person without
schizophrenia. Not only do complications from the disorder and treatment harm
schizophrenics over time, two thirds of people whose deaths are related to schizophrenia
commit suicide (Auquier, Lancon, Rouillon, & Lader, 2007; Brown, 1997). The
epidemiology of schizophrenia is unclear; there have been some studies that link
schizophrenia with the presence of specific genes (Owen, Craddock, & O’Donovan, 2005),
however it is apparent that the genetic component is not the only factor determining
whether or not schizophrenia will develop. Monozygotic twins share roughly a 50%
concordance rate of schizophrenia, which implies that environmental factors are also
important for the development of the disorder (Owen et al., 2005).
Emil Kraepelin (1896) began constructing what is now the modern framework of
schizophrenia. Kraepelin described the disorder as “dementia praecox” which means early
dementia. Dementia is normally a condition that develops later in life; early dementia
refers to the common early onset of schizophrenia. Kraepelin also developed a list of
symptoms exhibited by people with the disorder. Dementia praecox was later termed
schizophrenia by Eugene Bleuler (1911). The root of the word schizophrenia means “split

1

mind.” The term refers to the disconnection between the mind and actions of someone
afflicted with schizophrenia.
Symptoms
The symptoms of schizophrenia can be classified into two main categories: positive
and negative (APA, 2000). The term positive symptoms refers to symptoms that
exaggerate or distort normal functioning, while the term negative symptoms refers to the
absence or reduction of normal functions (APA, 2000). Positive symptoms include
hallucinations, disorganized thought and speech, delusions, catatonic behavior, and
disorganized behavior.
Hallucinations are false perceptions of experiences involving distortion of the
senses. Auditory hallucinations are the most common, but some people with schizophrenia
have hallucinations that involve other or multiple senses. Disorganized thought is a very
common feature of schizophrenia (APA, 2000) which is most noticeable when hearing a
person with schizophrenia speak. Schizophrenics displaying disorganized thought and
speech jump quickly from one topic to the next while making very vague, if not nonexistent, associations. Delusions are false beliefs. People with schizophrenia display
several different types of delusions. The most common form of delusion for people with
schizophrenia to experience is delusions of persecution (APA, 2000). Delusions of
persecution include thoughts that people are trying to single out and harm the person
experiencing them (e.g. big brother is watching me; everyone’s trying to get me).
Referential delusions also occur as nonspecific things directed at person with
schizophrenia (e.g. codes in advertisements directed toward the individual). Religious

2

delusions are also possible symptom (e.g. the person with schizophrenia claims to be a
martyr). Another form of delusion endured by some schizophrenics is a delusion of
grandeur (e.g. belief of being the king of the universe).
Disorganized behavior is behavior that does not make sense to an average person.
Schizophrenics do not display clear purpose guiding their behavior. They dress themselves
inappropriately based on the weather. They sometimes display loud outbursts in public for
no apparent reason. These behaviors can severely impair a schizophrenic’s ability to
perform normal daily activities (APA, 2000). Catatonic motor behavior refers to a lack of
reactivity to one’s environment and is characterized by maintaining a rigid, uncomfortable
position for an extremely long amount of time. Although disorganized thoughts and
behaviors are considered positive symptoms in the Diagnostic and Statistical Manual of
Mental Disorders IV, TR (DSM-IV-TR; APA, 2000), some research suggests that they
have a different pathology than other positive symptoms (Arndt et al. 1991).
In addition to positive symptoms, people with schizophrenia are also subject to
negative symptoms. Examples of negative symptoms include avolition, flat affect,
anhedonia, and alogia. Avolition is characterized by the lack of desire, drive, or goalmotivated behavior. Flat affect is the reduction of the expression of emotions, sometimes
apparent in people suffering from depression. Alogia in terms of schizophrenia is known as
poverty of speech and refers to a general inability to engage in unprompted conversation.
Instead of a normal flowing conversation, schizophrenics displaying alogia commonly will
answer questions with one word answers, if at all. Anhedonia is defined as the inability to
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receive pleasure from normally pleasurable experiences (e.g. no longer enjoy the taste of
favorite foods).
Another symptom common in schizophrenia is cognitive impairment, and most
schizophrenics have some degree of cognitive deficit (Meltzer, Thompson, Lee, & Ranjan,
1996). On average, people with schizophrenia perform in the lowest ten percent of the
population on cognitive tests (Keefe, 2007). Cognitive impairment has historically been
considered a negative symptom (loss of cognitive ability), but because of its unique effects,
it has more recently started to be considered a separate category of symptoms.
Schizophrenics may show severe cognitive deficits, including severe problems with
executive functioning, working memory, verbal memory, verbal fluency and attention
(Keefe, 2001) as well as moderate impairments in delayed recall, visuo-motor skills, and
distractibility; and mild impairments in delayed recognition, perceptual skills, and IQ
(Keefe, 2007). The degree of cognitive impairment in a schizophrenic’s is very predictive
of their functional outcome (Green, Kern, Braff, & Mintz, 2000; McEvoy, 2008). The
MATRICSTM initiative (Measurement and Treatment Research to Improve Cognition in
Schizophrenia) was established by the National Institute of Mental Health to encourage
researchers to examine how we should address the issue of cognitive deficits in
schizophrenia (Green, Nuechterlein, Gold, Barch, Cohen, Essock, Fenton, Frese, Goldberg,
Heaton, Keefe, Kern, Kraemer, Stover, Weinberger, Zalcman, & Marder, 2004). Because
of this initiative, achieving cognitive improvement for people with schizophrenia has
become a target for researchers and will help drive the development of novel therapeutic
agents that address that issue (Laughren & Levin, 2006; Meltzer & McGurk, 1999).
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While there are a variety of symptoms displayed by people schizophrenics, they do
not necessarily display all of the possible symptoms. Only a few of the listed symptoms
need to be present to be diagnosed with schizophrenia. The DSM-IV-TR recognizes
several different categories of schizophrenics, including paranoid, disorganized and
catatonic subtypes.
Pharmacological Treatments for Schizophrenia
Until the early 1950s there were no effective treatments for schizophrenia, leaving
no option for people with schizophrenia beyond being permanently institutionalized. In
1952, Henri Laborit was using promethazine, the original phenothiazine, during anesthesia.
Later that year, other French researchers studied a second phenothiazine, chlorpromazine,
to use in pre-operation patients because of its ability to produce conscious sedation and
detachment from external stimuli, known as a neuroleptic state (Julien, 2004). Because of
the tranquilizing effect it had on patients, chlorpromazine was classified as the first
neuroleptic drug and introduced in 1954 as the first pharmacological treatment for
schizophrenia. The term neuroleptic was used to describe what are now known as typical,
classic, or first-generation antipsychotic drugs (APDs).
The emergence of chlorpromazine as a treatment for schizophrenia had an
enormous effect on the mental health profession as a whole, as patients were able to be
maintained on medication for a disorder that did not have any other effective treatments
(Thompson, 1977). The treatment of schizophrenia with chlorpromazine made such an
impact on the field of mental health that it also facilitated the beginnings of behavioral
pharmacology (Thompson, 1977). While typical APDs were very beneficial to the
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treatment of schizophrenics, they were only effective at treating the positive symptoms of
the disorder, without addressing the negative symptoms or cognitive deficits associated
with the disorder.
Following the success of chlorpromazine, several other antipsychotic medications
were developed and marketed in the late 1950s and into the 1960s including reserpine,
haloperidol, droperidol, loxapine, and molindone (Julien, 2004). These typical
antipsychotics have similar mechanisms of action; they all reduce dopamine activity in the
brain, primarily with antagonist activity at D2 receptors (Julien, 2004). Dopamine
antagonism contributes to the therapeutic effect of the medications, but it also is
responsible for producing extrapyramidal motor side-effects (EPS) (Van Rossum, 1966;
Carlsson & Lindqvist, 1963). EPS are debilitating side-effects that resemble the motor
impairments found in patients with Parkinson’s disease, including tremors and rigidity,
involuntary movements, and akathesia (body restlessness). Because these side-effects often
accompanied therapeutic doses of typical APDs, they were thought to be necessary
components of treatment. As more drugs to treat schizophrenia were assessed, it became
clear that it was possible to develop drugs with therapeutic efficacy that are not susceptible
to producing EPS (Julien, 2004). The first drug developed that fit this profile was
clozapine.
Clozapine
Clozapine was first developed by Wander Laboratories in 1959, as a member of a
family of drugs being developed termed “…tricyclic antidepressants but with neuroleptic
properties (Hippius, 1999),” but was not applied to the treatment of schizophrenia until the
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early 1970s. Clozapine was first reported to have very similar properties to chlorpromazine
in animals, and thus not very interesting, but because of some relevant behavioral
properties that it displayed it was recommended to be tested in humans: Clozapine did not
produce catalepsy similar to chlorpromazine and other antipsychotics, and it also increased
the pain tolerance of laboratory animals (Crilly, 2007). Human tests produced favorable
results, clozapine was shown to have antipsychotic properties, and it did not cause the
undesirable side effects (EPS) that all other antipsychotic drugs produced (Crilly, 2007).
Clozapine was introduced as an APD in Europe in 1974, but was soon pulled off the
market after a small number of patients died because of complications related to
agranulocytosis caused from taking the medication (Julien, 2004). Agranulocytosis is a
condition that causes a reduction in circulating white blood cells in the bloodstream, which
in turn causes susceptibility to disease and death. Despite this risk, clozapine remained of
interest to researchers because of its therapeutic ability in patients with schizophrenia. A
1988 study by Kane and colleagues reported that 30% of treatment resistant schizophrenics
showed therapeutic response to the medication, while only 4% of those treated with
chlorpromazine responded (Kane, Honigfeld, Singer, & Meltzer, 1988). Because of the
ability to treat patients resistant to other drugs, the reduced chance of EPS, and the
discovery that the agranulocytosis, which only affects 0.8% of patients taking clozapine
(Breier, Tran, Herrea, Tollefson, Bymaster, 2001), is reversible after discontinuation of the
medication and can be monitored with regular blood testing, clozapine was reintroduced to
the U.S. market in 1990 (Crill, 2007).
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Clozapine is considered the first atypical antipsychotic drug (APD), which refers to
its ability to treat both positive and negative psychotic symptoms without producing
debilitating motor side effects such as EPS (Arnt & Skarsfeldt, 1998; Ellenbroek, 1993).
Clozapine has high clinical efficacy, especially in treatment-resistant schizophrenic
patients (Kane et al., 1988). Clozapine also has been shown to lower the risk of suicide in
people with schizophrenia compared to classical anti-psychotic drugs, which is an
important aspect of treatment, considering the increased risk of suicide in people with
schizophrenia (Meltzer, 1998, Meltzer, 2001). Because of these reasons, CLZ is viewed as
an atypical antipsychotic of great interest. It would be beneficial to develop a drug with
similar mechanisms as CLZ, without the possible side-effect of agranulocytosis.
N-desmethylclozapine
Investigators have recently wondered whether or not N-desmethylclozapine
(NDMC) contributes to the clinical efficacy of clozapine (CLZ). NDMC is the major active
metabolite of CLZ and is found in humans treated with CLZ at plasma levels almost as
high as CLZ itself (Flanagan, R., Yusufi, B., & Barnes, T., 2003). Though the metabolism
of CLZ to NDMC varies greatly, as studies have cited NDMC recorded at levels between
20 and 150% of the parent compound (CLZ) (Bondesson & Lindstrom, 1988; Perry et al.,
1991). Researchers studying the metabolism of CLZ, noted that NDMC is formed by the
demethylation of CLZ by CYP3A4 and CYP1A2 isoforms of P450 enzymes (Eiermann et
al., 1997; Olesen & Linnet, 2001). Many studies have shown that patients with higher
ratios of NDMC to CLZ in the bloodstream show more reduction of both positive and
negative symptoms of schizophrenia (Frazier, Cohen, Jacobsen, Grothe, Flood,
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Baldessarini, Piscitelli, Kim & Rapoport, 2003; Mauri, Volonterie, Dell’Osso, Regispani,
Papa, Baldi, & Bareggie 2003) and is predictive of cognitive improvement and a greater
quality of life in patients with schizophrenia, suggesting an important contribution of
NDMC to the clinical efficacy of CLZ (Weiner et al., 2004).
NDMC has been found to be active in vivo through examining the relationship
between acute administration of NDMC and Fos protein expression in the forebrain of rats
(Young, Meltzer, & Deutch, 1998). Fos protein expression was increased in the medial
prefrontal cortex and nucleus accumbens but not in the dorsal striatum, indicating similar
activity to that of its parent drug, CLZ (Young et al., 1998). NDMC has been shown to
reverse hyperactivity induced by the dopamine receptor agonist amphetamine and the
NMDA receptor antagonist MK-801, which are preclinical models of psychotic behavior
(see Lameh, Burstein, Taylor, Weiner, Vanover, & Bonhaus, 2007). Early clinical trials
with ACP-104 showed tolerability and safety at doses that showed signs of possible
antipsychotic activity (Tamminga, Eamma, Ibraham, Jain, Taylor, Vanover, Hacksell,
Brann, & van Kammen, 2006). NDMC (ACP-104) was recently found to be ineffective in
treating psychotic symptoms compared to VEH during phase II clinical trials with
conducted by ACADIA Pharmaceuticals, suggesting it may not be a likely stand-alone
treatment for schizophrenia, but could be used in combination with other APDs (Reuters,
2008).
Like CLZ, NDMC has a diverse pharmacological profile, with affinity for many
different receptors/receptor subtypes. The receptor pharmacology of NDMC is similar to
that of CLZ in some ways, but quite different in others. These differences in drug-receptor
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interactions may contribute to the overall therapeutic efficacy of CLZ. Overall, the
contributions of NDMC to the therapeutic effects of CLZ are largely unknown. One
important difference in NDMC relative to CLZ is that NDMC is a D2 partial agonist. D2
partial agonism has been hypothesized to be beneficial for the treatment of schizophrenia.
Partial agonists can also act as agonists at presynaptic D2 autoreceptors and function as
antagonists at postsynaptic receptors (Lameh, et al., 2007). This is hypothesized to reduce
dopamine activity in the brain more effectively than an antagonist alone, producing a more
therapeutically effective treatment (Lameh et al., 2007).
While many typical and atypical antipsychotic drugs (APDs) are antagonists at D2
receptors, D2 partial agonism has been investigated more recently because of the advent of
the partial D2 agonist aripiprazole. Aripiprazole has shown to be effective at treating
symptoms of schizophrenia without reduced motor side-effects (Lameh et al., 2007).
Aripiprazole displays efficacy in treating both positive and negative symptoms of
schizophrenia, as well as being tolerable to patients and safe to use (Potkin et al., 2003).
The success of aripiprazole in the treatment of schizophrenia gives more credibility for the
role of D2 partial agonism, and thus NDMC, in treating schizophrenic symptoms.
Binding Affinities of Clozapine and N-desmethylclozapine
Clozapine has a very diverse binding profile, displaying an affinity for many
different receptors including serotonergic, histaminergic, adrenergic, muscarinic receptors,
opioid and others (Schotte, Janssen, Gommeren, Luyten, VanGompel, Lesage, DeLore, &
Leysen, 1996). Some research has shown an important role of the serotonergic and
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noradrenergic systems in the therapeutic efficacy of clozapine (Meltzer, Matsubra, & Lee,
1989).
Dopaminergic Receptor Activity
NDMC binds to dopamine receptor subtypes D2, D3, and D4 (Lameh, Burstein,
Taylor, Weiner, Vanover, & Bonhaus, 2007; Burstein, Ma, Wong, Gao, Pham, Knapp,
Nash, Olsson, Davis, Hacksell, Weiner, & Brann, 2005). CLZ also binds to the
aforementioned dopamine receptor subtypes. CLZ and NDMC are both antagonists at D4
receptors (Lameh et al., 2007), but it is not known if D4 receptor activation plays a role in
the treatment of schizophrenia (Corrigan Gallen, Bonura, & Merchant, 2004). As shown in
Table 1, CLZ shows different activity at D2 and D3 receptors than NDMC; while it is an
antagonist or inverse agonist, NDMC is a partial agonist (Lameh et al., 2007).
Muscarinic Receptor Activity
NDMC has been found to bind to all muscarinic receptor subtypes (Weiner,
Meltzer, Veinbergs, Donohue, Spalding, Smith, Mohell, Harvey, Lameh, Nash, Vanover,
Olsson, Jayathilake, Lee, Levey, Hacksell, Burstein, Davis, & Brann, 2004). CLZ also
binds to all 5 muscarinic receptor subtypes. Although both compounds bind to the
receptors, differences in the actions of the drugs have been observed. The most obvious
difference is seen at the M1 receptor subtype. As shown in Table 2, NDMC is an
efficacious partial or full agonist at M1 receptors, while CLZ has been classified as having
both antagonist and partial agonist properties at the receptor subtype (Sur, Mallorga,
Wittmann, Jacobson, Pascarella, Williams, Brandish, Pettibone, Scolnick, & Conn, 2003;
Davies, Compton-Toth, Hufeisen, Meltzer, & Roth, 2005). This partial agonistic action at
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Table 1
RSAT assay (receptor selection and amplification technology) measuring agonist,
antagonist, and inverse agonist activity of NDMC and CLZ at dopamine receptors
Compound
Receptor
D2
D3
D4
Receptor
D2
D3
D4
Receptor
D2
D3
D4

n-desmethylclozapine
Agonist
pEC50
%Efficacy
7.8 + 0.5
32 + 9%
7.3 + 0.3 (49%)

clozapine
Agonist
pEC50
%Efficacy
NA
NA

NA
Antagonist
pKi
7.2 + 0.1
6.8 + 0.4
7.2 + 0.5
Inverse Agonist
pIEC50
NA
NA
NA

NA
Antagonist
pKi
7.1 + 0.5
7.1 + 0.4
8.1 + 0.2
Inverse Agonist
pIEC50
7.1 + 0.5
7.6 + 0.3
NA

Agonist potency is expressed as pEC50 (-logEC50) and agonist efficacies were normalized
in comparison to the efficacy of the dopamine agonist pergolide. Antagonist activity was
measured in the presence of a fixed concentration of pergolide and are expressed as pKi (logKi). Ki values were determined using antagonist IC50 values by correcting for agonist
concentration and pEC50 using the Cheng-Prusoff equation (Ki=IC50/[1+(agonist)/EC50
agonist]). Inverse agonist activity is shown as pIEC50 (-logIEC50) and show potency of
ligand in reversing constitutive activity of receptor without an agonist added. Data
presented are means + standard deviations. NA = no significant agonist activity up to 10
µM or no significant antagonist or inverse agonist activity up to 1 µM. This table is
derived from data presented in previous papers (Burstein et al., 2005; Lameh et al., 2007).
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Table 2
RSAT assay measuring agonist and antagonist activity of NDMC and CLZ at muscarinic
receptors
Compound
Receptor
M1
M2
M3
M4
M5
Receptor
M1
M2
M3
M4
M5

n-desmethylclozapine
Agonist
pEC50
%Efficacy
7.3 + 0.1
72 + 5%
6.5 + .02
106 + 19%
6.5 + 0.2
27 + 4%
6.9 + 0.2
87 + 8%
7.6 + 0.3
48 + 6%
Antagonist
pKi
NA
NA
6.8 + 0.7
NA
NA

clozapine
Agonist
pEC50
%Efficacy
7.7 + 0.4
24 + 3%
6.2 + .01
65 + 8%
NA
7.4 + 0.1
57 + 5%
NA
Antagonist
pKi
7.8 + 0.2
NA
8.2 + 0.2
NA
7.5 + 0.3

Agonist potency is expressed as pEC50 (-logEC50) and agonist efficacies were normalized
in comparison to the efficacy of the muscarinic agonist carbachol. Antagonist activity was
measured in the presence of a fixed concentration of carbachol and are expressed as pKi (logKi). Ki values were determined using antagonist IC50 values by correcting for agonist
concentration and pEC50 using the Cheng-Prusoff equation (Ki=IC50/[1+(agonist)/EC50
agonist]). Data presented are means + standard deviations. NA = no significant agonist
activity up to 10 µM or no significant antagonist or inverse agonist activity up to 1 µM.
This table is derived from data presented in previous papers (Weiner et al, 2004; Lameh et
al., 2007).
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the M1 muscarinic receptor subtype is unique to most known APDs.
Serotonergic Receptor Activity
NDMC and CLZ both have a high affinity for 5-HT2A receptors (Kongsamut,
Roehr, Cai, Hartman, Weissensee, Kerman, Tang, & Sandrasagra, 1996). They are both
classified as inverse agonists at that receptor subtype, as shown on Table 3. Because 5HT2A antagonism has been shown to modulate dopamine transmission, it has been
hypothesized that 5-HT2A antagonism or inverse agonism may block transmission at both
5HT2A receptors and dopamine receptors (Kongsamut et al., 1996; Weiner et al., 2004).
NDMC and CLZ both display high affinity for 5-HT2C receptors and are inverse agonists
in in vitro assays (Lameh et al., 2007). NDMC and CLZ are both partial agonists at 5-HT1A
receptors (Newman-Tancredi, Assié, Leduc, Ormiére, Danty & Cosi, 1998), which may
offer benefits to the treatment of schizophrenia by reducing EPS, and alleviating negative
symptoms (Lameh et al., 2007; Newman-Tancredi et al., 1998). NDMC and CLZ are both
high affinity inverse agonists at 5-HT6 and 5-HT7 receptors, with similarly moderate
potency (Weinter et al., 2004).
Histaminergic Receptor Activity
Both CLZ and NDMC are antagonists at H1 receptors. This antagonism has been
linked to the sedating properties of many APDs along with other effects such as weight
gain. Although both CLZ and NDMC bind to H1 receptors with similar affinity, CLZ
displays up to 50 times more intrinsic activity than NDMC at those receptors as shown on
Table 4 (Weiner et al., 2004). It is expected that NDMC could show less sedating effects in
vivo because of this reduced activity at H1 receptors.
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Table 3
RSAT assay measuring agonist, antagonist, and inverse agonist activity of NDMC and
CLZ at serotonin receptors
Compound
Receptor
5-HT1A
Receptor
5-HT1A
5-HT2A
5-HT2C
Receptor
5-HT2A
5-HT2C
5-HT6
5-HT7

n-desmethylclozapine
Agonist
pEC50
%Efficacy
6.3 + 0.2
69 + 7%
Antagonist
pKi
NA
8.1 + 0.3
7.7 + 0.2
Inverse Agonist
pIEC50
7.7 + 0.4
7.3 + 0
6.9 + 0.1
7.3 + 0.1

clozapine
Agonist
pEC50
%Efficacy
6.6 + 0.4
45 + 10%
Antagonist
pKi
NA
8.0 + .05
7.4 + 0.2
Inverse Agonist
pIEC50
7.9 + 0.3
6.7 + 0.1
7.0 + 0.2
7.4 + 0.1

Agonist potency is expressed as pEC50 (-logEC50) and agonist efficacies were normalized
in comparison to the efficacy of the serotonergic agonist 5-Carboxamidotryptamine.
Antagonist activity was measured in the presence of a fixed concentration of 5Carboxamidotryptamine and are expressed as pKi (-logKi). Ki values were determined
using antagonist IC50 values by correcting for agonist concentration and pEC50 using the
Cheng-Prusoff equation (Ki=IC50/[1+(agonist)/EC50 agonist]). Inverse agonist activity is
shown as pIEC50 (-logIEC50) and show potency of ligand in reversing constitutive activity
of receptor without an agonist added. Data presented are means + standard deviations. This
table is derived from data presented in previous papers (Weiner et al, 2001; Lameh et al.,
2007).
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Table 4
Activity of NDMC and CLZ at H1 histamine receptors using RSAT, PI hydrolysis, and
Binding Assays
Compound
Receptor/Assay
RSAT
H1

n-desmethylclozapine

clozapine

pKi
8.1 + 0.2

pKi
9.8 + 0.2

pKi
8.4 + 0.6

pKi
9.7 + 0.4

pKi
8.3 + 0.1

pKi
8.5 + 0.2

PI hydrolysis
H1
Receptor Binding
H1

Antagonist activity was measured in the presence of a fixed concentration of histaminergic
agonist histamine and are expressed as pKi (-logKi). Ki values were determined using
antagonist IC50 values by correcting for agonist concentration and pEC50 using the ChengPrusoff equation (Ki=IC50/[1+(agonist)/EC50 agonist]). Binding was measured using the
radioligand [3H]-pyrilamine. pKi values were calculated using IC50 values from binding
competition assays by correcting for the dissociation constant (Kd) and concentration of
the radioligand used in each assay using the Cheng-Prusoff equation. Data are expressed as
means + standard deviations. This table is adapted from data presented in a previous study
(Lameh et al., 2007).
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Opioid Receptors
NDMC and CLZ show selective delta-opioid agonist activity using in vitro assays
(Onali & Olianas, 2007). NDMC was found to have full agonist activity at the delta-opioid
receptor subtype in human cloned receptors expressed in Chinese hamster ovary cells
(Onali & Olianas, 2007). NDMC was reported to have 82% of full agonist efficacy at the
delta opioid receptor, while CLZ only showed 33% efficacy (Onali & Olianas, 2007).
Opioid receptor involvement in CLZ therapeutic action has not been thoroughly studied.
Given that NDMC is a selective agonist at delta opioid receptors, they may be important to
the therapeutic action of CLZ.

α-Adrenoreceptors
NDMC antagonist activity at α1A adrenoreceptors creates orthostatic hypotension
(Takata, Kurihara, Suzuki, Okubo, & Kato, 1999), which is side effect produced by many
APDs. Both NDMC and CLZ have antagonistic properties at the α1A adrenoreceptor
(Lameh, 2007), but CLZ shows a five-fold higher affinity than NDMC as shown in Table
5. This lower affinity of NDMC could produce less potential side-effects if used as a
treatment without CLZ.
Drug Discrimination
Drug discrimination is a valuable behavioral assay used in pharmacological
research based on basic Pavlovian and Skinnerian principles of learning. Subjects are
trained to discriminate the internal stimuli associated with a certain drug (training drug)
from those associated with vehicle (saline-like or inactive solution). After subjects have
been trained in a drug discrimination paradigm, usually using an operant response such as
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Table 5
Activity of NDMC and CLZ at α1A and α1B Adrenoreceptors using RSAT, PI hydrolysis, and
Binding Assays
Compound
Receptor/Assay
RSAT
α1A
α1B

n-desmethylclozapine

clozapine

pKi
7.2 + 0.4
7.4 + 0.3

pKi
8.0 + 0.2
8.1 + 0.3

pKi
7.5 + 0.4
8.5 + 0.1

pKi
8.7 + 0.2
9.3 + 0.2

pKi
7.3 + 0.1

pKi
8.1 + 0.1

PI hydrolysis
α1A
α1B
Receptor Binding
α1A

Antagonist activity was measured in the presence of a fixed concentration of adrenergic
agonist phenylephrine and are expressed as pKi (-logKi). Ki values were determined using
antagonist IC50 values by correcting for agonist concentration and pEC50 using the ChengPrusoff equation (Ki=IC50/[1+(agonist)/EC50 agonist]). Binding was measured using the
radioligand [3H]-prazosin. pKi values were calculated using IC50 values from binding
competition assays by correcting for the dissociation constant (Kd) and concentration of
the radioligand used in each assay using the Cheng-Prusoff equation. Data are expressed as
means + standard deviations. This table is adapted from data presented in a previous study
(Lameh et al., 2007).
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lever pressing, nose-poking, or running a maze, they can recognize the specific
interoceptive cues of different drugs and these drugs can serve as discriminative stimuli in
drug discrimination paradigms to examine their pharmacological profiles (Overton, 1966;
& Harris & Balster, 1971). After the animal has successfully acquired the discriminative
stimulus, novel drugs can be assessed as to whether they will substitute for the training
drug (Harris and Balster, 1971). Drugs with similar receptor binding profiles or drugs in
the same pharmacological classes tend to substitute for each other in drug discrimination
generalization tests (Harris & Balster, 1971; Brady & Balster, 1981). In animals trained to
discriminate morphine, both heroin and methadone will substitute for discriminative
stimulus of morphine (Overton and Batta, 1979).
In order to assess compounds using drug discrimination, they must exert centrally
mediated effects. Drugs that do not cross the blood brain barrier are unable to be used as
discriminative stimuli (Schuster & Balster, 1977). This concept was demonstrated when
Schechter and Rosecrans showed that centrally acting, but not peripherally acting
antagonists blocked the discriminative stimulus of nicotine (1971). Centrally administered
drugs have also been found to serve as discriminative stimuli, showing the lack of
necessity of peripheral activity.
Discriminative Stimulus Properties of Clozapine
Clozapine has been established as a discriminative stimulus in many species of
animals including primates, rats, pigeons, and mice (Carey & Bergman, 1997; Goas &
Boston, 1978; Wiley & Porter, 1992; Hoenicke, Vanecek, & Woods, 1992; & Philibin,
Prus, Pehrson, & Porter, 2005). Clozapine has a diverse binding profile, but has been found
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to serve as a reliable discriminative stimulus. Goas and Boston were the first investigators
to establish clozapine as a discriminative stimulus in rats; training them to discriminate 6.0
mg/kg CLZ administered orally from vehicle using a two-lever operant procedure (Goas &
Boston, 1978). They also trained chlorpromazine (2.0 mg/kg, oral administration) versus
vehicle and chlorpromazine (2.0 mg/kg, oral administration) versus clozapine (6.0 mg/kg
oral administration) (1978). They found that haloperidol substituted for chlorpromazine,
but chlordiazepoxide failed to substitute in chlorpromazine discriminating subjects. None
of the drugs assessed (haloperidol, chlorpromazine, chlordiazepoxide, atropine, or a
combination of chlorpromazine and benztropine) fully substituted for clozapine in
clozapine-trained subjects, suggesting a specificity of the discriminative stimuli of atypical
antipsychotic drugs (Goas & Boston, 1978). Rats have also been trained to discriminate 20
mg/kg clozapine by route of intraperitoneal injection (i.p.) from 2.5 mg/kg haloperidol
(i.p.) using a T-maze learning procedure (Overton, 1982).
Porter and colleagues established clozapine as a discriminative stimulus in rats
using a 1.25 mg/kg dose (i.p.), and found that olanzapine, sertindole, and risperidone all
fully substituted, and quetiapine, thioridazine, and haloperidol partially substituted for
clozapine (Porter, Varvel, Vann, Philibin, & Wise, 2000). Remoxipride, chlorpromazine,
and fluphenazine all failed to substitute reliably for clozapine. Prus and colleagues showed
that the atypical APDs quetiapine, ziprasidone, and olanzapine, all substituted for
clozapine in rats trained to discriminate clozapine (5.0 mg/kg) from vehicle, while
sertindole and risperidone partially substituted for the CLZ discriminative stimulus (Prus,
Philibin, Pehrson, Stephens, Cooper, Wise, & Porter, 2005). They also found that the
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typical APD thioridazine produced full substitution, while typical APDs haloperidol,
fluphenazine, and chlorpromazine failed to substitute. The divergence of results between
these two studies shows the importance of training dose in assessing discriminative
stimulus substitution.
Another example of training dose importance is related to the muscarinic receptor
activity of clozapine. M1 receptors have been found to be an important component of
clozapine’s discriminative stimulus (Goudie, Smith, Taylor, Taylor, & Tricklebank, 1998;
Kelley & Porter, 1997; Nielsen, 1988; Prus, Baker, & Meltzer, 2004). Cross-generalization
of clozapine and scopolamine, a M1 antagonist, was reported by Kelly and Porter (1997) in
rats trained to discriminate 5.0 mg/kg clozapine (i.p.) from vehicle and rats trained to
discriminate 0.125 mg/kg (i.p.) scopolamine from vehicle. Goudie and colleagues
confirmed that scopolamine fully substitutes for clozapine in 5.0 mg/kg trained rats
(Goudie, et al., 1998). In a later study, rats were trained on 1.25 mg/kg clozapine (i.p.) and
scopolamine failed to generalize to that discriminative stimulus (Porter et al., 2000). This
suggests that rats trained on lower training doses (i.e. 1.25 versus 5.0 mg/kg, i.p.) may be
more sensitive to the specific differences in discriminative stimulus properties of typical
and atypical APDs and less sensitive to muscarinic cholinergic antagonism substituting for
the discriminative stimulus of CLZ (Porter et al., 2000; Goudie & Taylor, 1998).
Serotonergic antagonism has been proposed as one of the underlying mechanisms
of atypical APDs including clozapine (Meltzer et al., 1989), however it does not appear to
be a necessary component of clozapine’s discriminative stimulus in rats as 5-HT2A receptor
antagonists ketanserin and M100907 failed to substitute in subjects trained with 5.0 mg/kg
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clozapine (i.p.) (Goudie et al., 1998). In rats trained with 0.16 mg/kg (i.p.) MDL100,907, a
5-HT2A receptor antagonist, CLZ fully substituted for the training drug, showing
asymmetrical generalization to the training drug (Dekeyne, Iob, & Millan, 2003). Rats
trained to discriminate 5.0 mg/kg (i.p.) CLZ from VEH failed to substitute the 5-HT1A
receptor agonist, S-14506 and the 5-HT2B/2C receptor antagonist SB 200646A (Goudie et
al., 1998). Combined antagonism of both 5-HT2 and 5-HT1C receptors using
cyproheptadine, metergoline, mianserin, pizotifen, and fluperlapine, produced full
substitution for the discriminative stimulus in pigeons trained to discriminate 1.0 mg/kg
clozapine (i.m.) from saline (Hoenicke, et al., 1992). Pigeons failed to generalize the
discriminative stimulus of clozapine to antagonists that were selective for 5-HT2 over 5HT1C such as ketanserin, pirenperone, risperidone, and methiothepin (Hoenicke et al.,
1992). The data reflected that antagonism of both receptor subtypes was necessary to
produce full substitution for clozapine. The data produced in pigeon studies however, were
not replicated in rats, as the 5-HT2A/2B/2C receptor antagonist, ritanserin did not substitute
for clozapine in rats trained to discriminate 5.0 mg/kg clozapine (i.p.) from vehicle (Wiley
and Porter, 1992).
The role of H1 histaminergic antagonism in the discriminative stimulus of clozapine
has also been investigated. The H1 receptor antagonists, mepyramine, and pyrilamine failed
to substitute in subjects trained with 5.0 mg/kg clozapine (i.p.) in rats (Goudie et al., 1998)
and pigeons (i.m.) (Hoenicke et al., 1992) respectively. Kelly and Porter found that in rats
trained to discriminate 5.0 mg/kg (i.p.) from vehicle, cyproheptadine, a H1 receptor
antagonist, 5-HT receptor antagonist, and M1 receptor antagonist, fully substituted for the
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clozapine discriminative stimulus (1997). Thus, H1 appears to play a minor role of the
discriminative stimulus of clozapine in rats. The discriminative stimulus of clozapine in
clozapine trained rats (5.0 mg/kg i.p.) fails to generalize to drugs that display adrenergic
antagonism (Kelly and Porter, 1997; Nielsen, 1988), while Goudie and colleagues found
partial generalization of an α1-adrenoreceptor antagonist, prazosin, and partial
generalization (defined as 40% or above) of the α2-adrenoreceptor antagonist,
methoxyidazoxan (1998).
Discriminative Stimulus Properties of Clozapine in C57BL/6 mice
Clozapine has been established as a discriminative stimulus in C57BL/6 mice in a
limited number of studies (Philibin, Prus, Pehrson, & Porter, 2005; Philibin, Walentiny,
Vunck, Prus, Meltzer, & Porter, 2008). Mice trained to discriminate 2.5 mg/kg CLZ (s.c.)
fully generalized the discriminative stimulus to olanzapine, risperidone, sertindole,
ziprasidone, quetiapine, iloperidone, zotepine, and melperone (Philibin et al., 2005;
Philibin et al., 2008). Both drugs displaying partial agonism at the D2 receptor, aripiprazole
and NDMC did not substitute for CLZ. Haloperidol, perphenazine, and fluphenazine all
failed to substitute for the CLZ discriminative stimulus, while thioridazine and
chlorpromazine did fully substitute for the discriminative stimulus showing some
selectivity for atypical APD substitution over typical APD substitution (Philibin et al.,
2008; Philibin et al., 2005). Chlorpromazine and thioridazine both have strong affinities for
muscarinic and serotonergic receptors as compared to the other typical APDs examined
which may indicate that those receptors play an important role in the discriminative
stimulus of CLZ (Schotte et al., 1996). Selective ligand generalization tests produced
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different results than previously obtained in other species. Ritanserin, a 5HT2A/2B/2C
antagonist and MDL 100,907, a 5-HT2A antagonist, and prazosin, a α1 antagonist,
produced full substitution for the CLZ discriminative stimulus (Philibin et al., 2008).
Scopolamine, the muscarinic antagonist produced partial substitution to CLZ, while
amphetamine and fluoxetine did not substitute (Philibin et al., 2008).
Discriminative Stimulus Properties of N-desmethylclozapine
The discriminative stimulus properties of NDMC have not been established using
NDMC as a training drug prior to this study, although other investigators have assessed
NDMC in terms of generalization to other APDs (Prus, Pehrson, Philibin, Wood, Vunck,
& Porter, 2008; Prus, Philibin, Pehrson, & Porter, 2006). Rats trained to discriminate 1.25
mg/kg CLZ from 5.0 mg/kg (i.p.) CLZ from VEH in a three-choice operant drug
discrimination task failed to substitute NDMC for either training dose at doses of NDMC
up to 8.0 mg/kg (i.p.), however the authors noted that 8.0 mg/kg NDMC failed to produce
a significant decrease in response rate (Prus et al., 2006). Rats trained to discriminate 1.25
mg/kg CLZ (i.p.) failed to generalize NDMC to clozapine at doses up to 20 mg/kg (i.p.),
although doses of 5.0 and 10.0 mg/kg NDMC did substitute when administered in
combination with a small dose (.3125 mg/kg) of clozapine (Prus et al., 2008).
Trihexyphenidyl, an M1 receptor antagonist, failed to substitute for clozapine at any dose,
but when combined with 5.0 mg/kg of NDMC, they produced partial substitution for
clozapine, although response rate was significantly suppressed (Prus et al., 2008). These
studies suggest that there may be a role of M1 receptor antagonism mediating the
discriminative stimulus properties of CLZ. It also suggests that NDMC may have a similar
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binding profile to CLZ when combined with an M1 antagonist, which could yield novel
compounds to treat schizophrenia. Philibin and colleagues (2008) had similar findings in
C57BL/6 mice trained to discriminate 2.5 mg/kg (s.c.) CLZ from VEH, showing that
NDMC did not substitute for CLZ at doses up to 10.0 mg/kg, at which significant
reduction of response rate was observed. When NDMC was combined with a .625 mg/kg
(s.c.) dose of CLZ it produced full substitution at the 10.0 mg/kg (s.c.) dose of NDMC,
however it was accompanied by a significant decrease in response rates (Philibin et al.,
2008).
Development of Cross-Tolerance to Clozapine
APDs have been shown to exert their full therapeutic effect only after chronic
dosing of the drug (Kuhar and Joyce, 2003), furthermore APDs have differential effects
during repeated dosing versus acute administration (Varvel, Vann, Wise, Philibin, &
Porter, 2002) thus it is important that we assess the discriminative stimulus properties of
clozapine before and after repeated administration of itself. Goudie and colleagues found
that repeated administration of clozapine induced tolerance to its discriminative stimulus
effects in rats, and that the tolerance was reversed after a period of drug abstinence,
suggesting the cellular changes were pharmacodynamic (Goudie, Cooper, Cole, &
Sumnall, 2007). After showing these pharmacodynamic changes following repeated
clozapine administration, cyproheptadine was repeatedly administered to clozapine trained
discrimination animals, to determine whether or not development of cross-tolerance to the
clozapine discriminative stimulus would occur (Goudie et al., 2007). Cyproheptadine is an
anti-allergy medication that interestingly has a similar binding profile to clozapine and
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substitutes fully for clozapine without suppressing responding (Goudie et al., 2007).
Repeated administration of cyproheptadine produced tolerance to the clozapine
discriminative stimulus, suggesting similar pharmacodynamic changes as those produced
by repeated administration of clozapine. In a separate study by Goudie and colleagues, rats
trained to discriminate 5.0 mg/kg CLZ (i.p.) from VEH were then administered either JL13
or olanzapine for ten consecutive days following completion of an initial dose-effect curve.
to assess development of cross-tolerance to the clozapine discriminative stimulus (Goudie
Cole, & Sumnall, 2007). Both olanzapine and JL13 were found to substitute for CLZ at
doses of 2.5 and 10.0 mg/kg respectively (Goudie et al., 2007). After treatment with
olanzapine or JL13, there was a significant induction of cross-tolerance to the CLZ
discriminative stimulus (Goudie et al., 2007), which was completely lost following 16 days
of no drug administration, suggesting pharmacodynamic modulation of receptors
mediating the CLZ discriminative stimulus. This development of cross-tolerance may be
an indicator of pharmacologically specific receptor modulation, which may be an indicator
of a therapeutically similar compound to CLZ following repeated administration.
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Rationale
Although the CLZ discriminative stimulus failed to generalize to NDMC when
NDMC was administered alone, it is important to assess whether or not NDMC can be
trained as a discriminative stimulus, and if so, if CLZ will substitute for it (Prus et al.,
2006; Prus et al., 2008). Understanding the discriminative stimuli of both NDMC and CLZ
is important for understanding receptor mechanisms responsible for CLZs therapeutic
effects, because NDMC is the major active metabolite of CLZ, and may be important for
treatment efficacy. It is also important to assess whether or not mice trained to discriminate
10.0 mg/kg NDMC (s.c.) can differentiate between typical and atypical APDs, which is
why haloperidol will also be tested for substitution.
Goudie and colleagues pointed out a major limitation of drug discrimination in the
fact that it typically assesses only acute drug effects, rather than those associated with
chronic administration of a drug as most APDs are used therapeutically (Goudie et al.,
2007). We may be able to develop better in vivo assays to assess the effect of chronic drug
administration. Goudie and colleagues have designed a way to study the tolerance inducing
effects of different compounds on the discriminative stimulus of clozapine in rats (Goudie
et al., 2007; Goudie et al., 2007). This present study will also assess the ability of NDMC
to produce tolerance to the discriminative stimulus of 2.5 mg/kg CLZ in C57BL/6 mice,
and whether or not those changes are pharmacodynamic in nature. Tolerance would be
indicated by parallel shifts to the right in the dose-response curve for CLZ. Generation of
reversible tolerance to the discriminative stimulus of CLZ would indicate that NDMC
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produces pharmacodynamic changes similar to that of its parent drug, CLZ, and would
suggest that similar receptor mediated changes are produced by the two compounds.
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Methods
Experiment 1 NDMC Discrimination
Subjects Experiment 1
Twelve experimentally naïve, adult male C57/BL6NHsd-wild type mice (20-25g)
obtained from Harlan Laboratories (Indianapolis, IN) were housed individually in clear plastic
cages (Philibin, Prus, Pehrson, & Porter) with steel wire fitted tops and wood chip bedding
(sanichips, Teklad, Madison, WI). Mice were transported daily (5-7 days per week) from the
vivarium (12 hour light-dark cycle, lights on at 6 a.m.) to the laboratory where experimental
training and testing sessions occurred. The vivarium temperature remained between 22 and 24
degrees Celsius. After one week of acclimation, the subjects were food deprived to 85-90% of
their free feeding body weights and were maintained on a food restricted diet of standard
rodent chow (Harlan Teklad Lab Diets, Teklad LM-485). Water was available ad libitum in the
home cages. The Guide for Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, National Academy Press, 1996) was followed and the Institutional Animal
Care and Use Committee at Virginia Commonwealth University (VCU) approved the
procedures that were used in the present study (IACUC Protocol AM 10284).
Drugs Experiment 1
N-desmethylclozapine (NDMC; provided by Herbert Y. Meltzer), Clozapine (CLZ;
atypical antipsychotic drug; gift from Novartis, Hanover, NJ), haloperidol (HAL; typical
antipsychotic drug; Sigma-Aldrich Chemical Company, St. Louis, MO) were dissolved in
distilled water and a small quantity (approximately two drops per 50 ml) of 85% lactic acid.
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All drugs were administered subcutaneously (Philibin et al.) with a volume of 10 ml/kg body
weight with a 30 min pre-session injection time.
Apparatus Experiment 1
Testing was conducted in six standard computer-interfaced operant conditioning
chambers (Model ENV-307A, Med Associates Inc., St. Albans, VT) each containing two
retractable levers in the left and right positions (8 cm apart) on the front panel of the operant
chamber. The levers extended 0.8 cm into the chamber and were positioned 2.5 cm above a
grid floor constructed of parallel stainless steel rods. Centered between them was a recessed
food trough into which a liquid dipper delivered 0.02 ml of sweetened-milk (by volume: 150
ml powdered milk, 150 ml sugar, and 500 ml water). The inner test chambers consisted of a
15 cm L X 11.5 cm D X 17.5 cm H area surrounded by an aluminum framed box with a single
Plexiglas side door. Test chambers were housed in sound attenuating chambers equipped with
ventilation fans. MED-PC software (Version 1.17, Med Associates Inc.) was used to control
the operant sessions and record data.
Training Procedures
Magazine Training Experiment 1
Before beginning magazine training mice were exposed to sweetened milk in small
bottle caps for 30 minutes in the home cage once a day for 2 days. Mice were magazine trained
for 2 sessions. During the 15 minute magazine training sessions, no levers were available in
the operant test chamber. Sweetened milk was delivered noncontingently on a fixed time 5
second (FT 5 sec) delivery schedule (i.e., a single presentation of sweetened milk was
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delivered by raising the dipper cup every 5 seconds and holding in the up position for 3
seconds before filling the dipper again).
Lever-Press Training Experiment 1
Lever-press training began upon completion of magazine training. A single lever (the
vehicle-paired lever) was extended inside the chamber. Each subject was placed in the operant
chamber and trained to press the levers for 0.02 ml of sweetened milk on a fixed ratio one
(FR1) schedule of reinforcement, in which the reinforcer was delivered after every lever
press(dipper was available for 3 sec.). Subjects were trained to lever press on a single lever
(i.e. the VEH-paired lever) until drug administration began. The position of the drugassociated lever (left vs. right) was counterbalanced between the groups of subjects to control
for olfactory cues (Extance and Goudie 1981). The value of the FR was gradually increased
over the next 6 sessions until FR10 was obtained. After response rates were consistently higher
than 10 responses per minute drug discrimination training began.
NDMC Discrimination Training Experiment 1
Subjects were then injected daily with a vehicle solution (VEH) 30 min prior to each
training session. The VEH-associated lever was extended in the test chamber and responding
was reinforced according to an FR 10 schedule. After response rates were consistently above
10 responses per minute (RPM), subjects were administered 2.5 mg/kg NDMC injections 30
min prior to training sessions and were only presented with the NDMC-associated lever
(opposite of the VEH-associated lever). Once response rates stabilized at over 10 responses per
minute, two-lever training began. During two-lever training sessions both levers were
extended in the operant chamber. The subjects were administered NDMC or VEH injections
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according to a double alternation sequence (i.e., DDVVDDVV). On days when NDMC was
administered, only responding on the NDMC associated lever was reinforced. On days when
vehicle was administered, only responding on the VEH associated lever was reinforced.
Responses on the incorrect lever reset the ratio requirement on the correct lever. Subjects
received two-lever discrimination training until the training criteria were passed during 5 of 6
consecutive sessions.
NDMC Discrimination Training Criteria Experiment 1
Successful discrimination training was evaluated and assessed according to three
criteria: (1) the first completed first fixed ratio (FFR) of the schedule (FR10) was executed on
the appropriate lever (2) 80% or greater of the total responses made during the session
occurred on the appropriate lever and (3) response rate for the session equaled or exceeded 10
RPM. Control vehicle and NDMC tests were administered and passed prior to generalization
testing with all drugs. During control and test sessions, responses on both levers were
reinforced according to the FR10 schedule and the FR requirement was reset when switching
between levers occurred. The three training criteria also had to be met during the two
consecutive training sessions immediately prior to all test sessions. Subjects were initially
required to meet criteria 5 of 6 consecutive training sessions before beginning testing. In
addition to these restrictions subjects were not tested unless criteria were met in the previous
two training days. The two training days immediately preceding testing also had to include
both a NDMC and a VEH day (i.e. either VD or DV passed immediately prior to test day).
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NDMC Training Dose Adjustment Experiment 1
After 57 training sessions, 5 of 12 subjects met the training criteria with the 2.5 mg/kg
training dose in a mean of 44.6 double-lever sessions (range = 17 - 57 sessions). Response
rates and overall response percentage were generally acceptable; however the FFR
requirement was usually the limiting factor. Because only 5 of 12 subjects met criteria, the
training dose was increased to 5.0 mg/kg. Nine of twelve subjects obtained the discriminative
stimulus of 5.0 mg/kg NDMC. Two subjects failed to meet training criteria after 57 sessions
and were removed from the study; one subject was removed to begin 10.0 mg/kg
discrimination training.
After completing the NDMC dose effect curve (0.625 - 10.0 mg/kg), it was apparent
that subjects were failing to reliably generalize a training dose of NDMC to itself or a 10.0
mg/kg dose. A visual analysis of individual data revealed that test performance was dependent
upon the training condition immediately prior to testing. When subjects were trained with
NDMC prior to testing they responded appropriately, but when they were trained with VEH
immediately prior to testing they responded more on the VEH appropriate lever. Subjects were
then retested with the opposite condition on the day prior to testing from their first test with the
3 highest doses of the NDMC curve (2.5, 5.0 and 10.0 mg/kg) to compare the effect of
previous training sessions within subjects. After observing this dependency upon previous test
session, the training dose was increased to 10 mg/kg. The training criteria were also changed,
requiring the mice to meet the training criteria for 7 of 8 consecutive training sessions before
beginning testing.
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NDMC Discrimination Testing Procedures Experiment 1
Subjects were required to pass the training criteria (5 of 6 or 7 of 8 appropriate training
sessions) and pass both a NDMC and CLZ control test before beginning dose effect or
generalization curves. Generalization or substitution testing occurred with a minimum of 2
days between tests and only when the subject passed the day immediately prior to testing.
During 10.0 mg/kg training this criterion was changed and subjects were required to pass both
a VEH and NDMC training session in the two training sessions prior to testing to assure the
test subject was under stimulus control. After successful completion of vehicle and NDMC
control tests, a generalization dose effect curve was determined for NDMC (1.25 – 20.0 mg/kg
for 10.0 mg/kg trained mice). Substitution tests were then conducted with the atypical APD
CLZ and the typical APD HAL. Control tests were performed between each new test drug
with the training drug and vehicle to assess NDMC discriminative stimulus control.
Data Analysis Experiment 1
Med Associates Inc. software was used for all data recording during the experiments.
During training and testing sessions, percent-drug lever responding (%DLR) was calculated by
dividing the number of condition-appropriate responses (i.e. either NDMC or VEH lever) by
the total number of responses made during the session and multiplying by 100. Responses per
minute (RPM) was calculated by dividing the total responses made on both levers by 15
minutes. ED50 values (using 95% confidence intervals, C.I.) will be calculated for drugs that
substitute for the training drug in %DLR curves (drugs with mean %DLR > 80% are
considered to fully substitute for training drug, drugs with mean %DLR between 60 and 80 are
considered to partially substitute for training drug) using the least squares method of linear
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regression, analyzing the linear portion of the dose effect curve. The %DLR was excluded
from analysis for any mice if their response rate was less than 2 RPM, or if they failed to
complete a FFR. All response rate data were included for data analysis. Repeated measures
analysis of variance (ANOVA) was used to compare RPM for each dose of a given drug (GBSTAT software; Dynamic Microsystems, Inc., Silver Spring, MD). Significant ANOVA
results (p < 0.05) will be investigated using Newman-Keuls post hoc tests. In Experiment 2,
ED50 values and confidence intervals were examined to determine if ED50 values were
significantly different from each other and to assess development of tolerance to CLZs
discriminative stimulus.
Experiment 2 CLZ Discrimination: Evaluation of Cross-tolerance Induction Using NDMC
Subjects Experiment 2
Twelve experimentally naïve, adult male C57/BL6NHsd-wild type mice (20-25g)
obtained from Harlan Laboratories (Indianapolis, IN) were housed and kept in an identical
manner to those in Experiment 1.
Drugs Experiment 2
N-desmethylclozapine (NDMC; provided by Herbert Y. Meltzer) and Clozapine (CLZ;
atypical antipsychotic drug; gift from Novartis, Hanover, NJ) were dissolved in distilled water
and a small quantity (approximately two drops per 50 ml) of 85% lactic acid, sodium
hydroxide was added to buffer the solution to near ph 7. All drugs were administered
subcutaneously (Philibin et al.) at a volume of 10 ml/kg body weight with a 30 min pre-session
injection time.
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Apparatus Experiment 2
Six two-lever Med Associates mouse operant chambers were used exactly as described
in Experiment 1.
Training Procedures Experiment 2
Magazine and lever press training were conducted as in Experiment 1. Drug
discrimination training conditions were held constant except that subjects were only exposed
to one training dose (10.0 mg/kg) of NDMC. After Experiment 1, it became clear that
NDMC’s discriminative stimulus may not be very robust so the training criteria were kept at 7
of 8 consecutive sessions passed. The three training appropriate criteria were kept the same as
in Experiment 1 as during the 10.0 mg/kg training.
Twelve subjects began 10.0 mg/kg discrimination training, but one subject was
removed from the study after becoming ill. After 47 training sessions, only 3 of 11 remaining
subjects had met criteria for 7 of 8 consecutive sessions. While three subjects acquired the
training criteria in a mean of 23.3 sessions with a range of 17to 30 sessions (SEM 3.76), eight
of eleven subjects failed to establish 10.0 mg/kg NDMC as a discriminative stimulus after 48
double lever training sessions. Training was suspended and all subjects were given free access
to food and water for 14 days.
Clozapine Discrimination & Assessment of Cross-tolerance induced by N-desmethylclozapine
New free-feeding weights were calculated for subjects, though if there new weight was
lower, the original free-feeding weight was retained; subjects were reduced to 85-90% of their
newly calculated free-feeding weights over a period of 7 days. Subjects then began
discrimination training with 2.5 mg/kg CLZ training dose. The training procedures were
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identical to those in Experiment 1 when 10.0 mg/kg was used for the training dose except for
the training drug and dose used, and the training was conducted 7 days a week.
Clozapine Dose Effect Curve 1 (DEC 1) Experiment 2
After establishing CLZ as a discriminative stimulus, using procedures similar to those
in Experiment 1 (i.e. 7 of 8 sessions appropriate, NDMC and CLZ control tests passed),
subjects were trained for two sessions (VEH NDMC or NDMC VEH) and then a clozapine
dose-effect curve was generated including doses of 0.3125, 0.625, 1.25, 2.5, and 5.0 mg/kg.
Subjects were randomly assigned to complete the CLZ dose effect curve in either ascending or
descending order of test doses. Each test session were separated by two training sessions
(VEH, NDMC or NDMC VEH), and was not contingent upon training performance (Goudie et
al., 2007 & Goudie et al., 2007). Thus, each subject will complete the CLZ dose effect curve in
15 sessions after passing both of their initial VEH and NDMC control tests. Upon completion
of the CLZ dose-response curve (DEC 1), discrimination training was suspended and subjects
were administered 10.0 mg/kg NDMC, twice daily (9:00 am and 6:00 pm) for 10 consecutive
days (Goudie et al., 2006; & Goudie et al., 2007).
Clozapine Dose Effect Curve 2 (DEC 2) Experiment 2
Following ten days of NDMC administration mice were tested with three different
doses (0.3125, 1.25 and 2.5 mg/kg) of CLZ over three consecutive days, producing a new dose
effect curve. These tests were conducted on three consecutive days to prevent the loss of
tolerance that could occur if there was training days in between tests (Goudie et al., 2006 &
Goudie et al., 2007). Subjects were randomly assigned to complete dose-effect curves in
ascending or descending order of test doses. Following completion of the second dose effect
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curve, the mice will be given 16 days of drug abstinence to allow drug induced cellular
changes to return to normal functioning (Goudie et al., 2007 & Goudie et al., 2007).
Clozapine Dose Effect Curve 3 (DEC 3) Experiment 2
Following the 10 days of no drug administration or training, mice were trained for two
days, counterbalanced between two conditions (i.e. either VEH NDMC or NDMC VEH)
before generating a CLZ dose effect curve using the same methods as in DEC 1. Each test will
be separated by 2 training days. Subjects were assigned to complete dose-effect curves in
ascending or descending order of test doses. Following completion of DEC 3, subjects were
given 2 training days followed by testing 10.0 mg/kg CLZ, as this dose was added during DEC
2. After completion of the 10.0 mg/kg CLZ test, subjects completed both VEH and CLZ
control points with two training days (including VEH and CLZ) before each test.
Data Analysis Experiment 2
Med Associates Inc. software was used for all data recording during the experiments.
During training and testing sessions, percent-drug lever responding (%DLR) was calculated by
dividing the number of condition-appropriate responses (i.e. either NDMC or VEH lever) by
the total number of responses made during the session and multiplying by 100. Responses per
minute (RPM) was calculated by dividing the total responses made on both levers by 15
minutes. ED50 values (using 95% confidence intervals, C.I.) will be calculated for drugs that
substitute for the training drug in %DLR curves (drugs with mean %DLR > 80% are
considered to fully substitute for training drug, drugs with mean %DLR between 60 and 80 are
considered to partially substitute for training drug) using the least squares method of linear
regression, analyzing the linear portion of the dose effect curve. The %DLR was excluded
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from analysis for any mice if their response rate was less than 2 RPM, or if they failed to
complete a FFR. All response rate data were included for data analysis. Repeated measures
analysis of variance (ANOVA) was used to compare RPM for each dose of a given drug (GBSTAT software; Dynamic Microsystems, Inc., Silver Spring, MD). Significant ANOVA
results (p < 0.05) will be investigated using Newman-Keuls post hoc tests. In Experiment 2,
ED50 values and confidence intervals were examined to determine if ED50 values were
significantly different from each other and to assess development of tolerance to CLZs
discriminative stimulus. GraphPad Prism 5 software was used to create figures as well as
calculate regression lines and evaluate differences between dose effect curves.
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Results
Experiment 1
2.5 And 5.0 mg/kg NDMC Acquisition
The mice began discrimination training using a 2.5 mg/kg training dose of NDMC;
however, only 5 of 12 mice passed the training criteria (5 of 6 sessions) after 57 doublelever training sessions (Fig. 1) in a mean of 44.6 sessions (SEM 8.43) with a range 17-57
sessions. The training dose was increased to 5.0 mg/kg NDMC, and 9 subjects passed
training criteria (5 of 6 sessions) in a mean of 15.7 sessions (SEM 2.73) with a range of 6
to 29 sessions (Fig. 2). Two mice were removed from the study after failing to pass criteria
following 57 double-lever training sessions and the training dose was increased to 10.0
mg/kg for another mouse after 60 sessions of 5.0 mg/kg discrimination training.
5.0 mg/kg NDMC Generalization
These 9 mice completed a dose-effect curve including 0.625, 1.25, 1.77, 2.5, 5.0,
and 10.0 mg/kg doses of NDMC. The generalization data produced by 5.0 mg/kg NDMCtrained mice revealed that none of the doses tested produced full substitution for 5.0 mg/kg
NDMC including the training dose of 5.0 mg/kg (50.49% DLR) and 10.0 mg/kg (75.13%
DLR), indicating a loss of stimulus control (Fig. 3). Visual inspection of the data suggested
that the subjects’ lever choice on test days was being influenced by the training condition
on the day immediately prior to testing. To verify this, subjects were tested with doses of
2.5, 5.0, and 10.0 mg/kg NDMC with either VEH or NDMC training sessions immediately
prior to testing. The subjects were tested with the opposite condition the day before testing
to which they had been previously tested for these three doses. These data were then
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plotted based on the training condition (either NDMC or VEH) of the day prior to testing.
When a VEH training day preceded testing, the mice did not show full substitution for 2.5
mg/kg (35.59% DLR), 5.0 mg/kg (41.33% DLR), or 10.0 mg/kg (67.07% DLR) doses of
NDMC (Fig. 4). In contrast, when a NDMC training session preceded testing (Fig. 5),
doses of 2.5 mg/kg (93.03% DLR), 5.0 mg/kg (84.22% DLR), and 10.0 mg/kg (95.01%
DLR) all produced full substitution for the training dose of 5.0 mg/kg NDMC. Thus, these
results demonstrated that the 5.0 mg/kg dose of NDMC was not able to maintain a stable
discriminative stimulus.
10.0 mg/kg NDMC Acquisition
The 9 mice (plus the subject that failed to complete 5.0 mg/kg discrimination
training) began 10.0 mg/kg NDMC discrimination training after completing the 5.0 mg/kg
NDMC generalization curve. Ten subjects passed the 10.0 mg/kg NDMC discriminative
stimulus training criteria (7 of 8 sessions of criteria met) in a mean of 27.5 sessions (SEM
4.24) with a range of 14 to 58 sessions (Fig. 6).
10.0 mg/kg NDMC Generalization
NDMC was tested for substitution with doses 1.25, 2.5, 5.0, 7.1, 10.0, and 20.0
mg/kg. Doses of 10.0 mg/kg (83.95% DLR) and 20.0 mg/kg (86.92% DLR) NDMC fully
substituted for the training dose of 10.0 mg/kg NDMC (Fig. 7), while no other doses
substituted. Response rates were found to be significantly different (F 7, 63 = 2.94, p < .05),
however, Newman-Keuls post-hoc tests revealed there were no significant response rate
differences as compared to VEH control rate for any dose tested. The NDMC ED50 = 6.29
mg/kg (95% C.I. = 4.72- 8.40 mg/kg). The 10.0 mg/kg NDMC generalization curve was
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completed by eight subjects of the 10 that were trained. One subject failed to complete the
curve before becoming ill and had to be removed from the study, so the animal’s data were
omitted; one subject failed to pass testing criteria and was removed from the study. After
completing the generalization curve, the data were separated by the training condition
(either NDMC or VEH) that preceded testing, and subjects were tested with doses of 10.0
mg/kg or 20.0 mg/kg NDMC with the opposite training condition given prior to testing.
When subjects were trained with VEH prior to testing 10.0 mg/kg (73.16% DLR) produced
partial substitution and 20.0 mg/kg (98.23% DLR) produced full substitution for 10.0
mg/kg NDMC (Fig. 8). When subjects were trained with NDMC prior to testing 10.0
mg/kg (62.66% DLR) produced partial substitution and 20.0 mg/kg (84.26% DLR)
produced full substitution for 10.0 mg/kg NDMC (Fig. 9).
Clozapine Substitution Tests
Clozapine was tested for substitution with doses 0.15625, 0.625, 1.25, 2.5, and 5.0
mg/kg (Fig. 10). Six subjects completed the CLZ generalization curve; two of eight
subjects included in the 10.0 mg/kg generalization curve became ill and were removed
from the study before beginning the CLZ generalization curve. Clozapine produced full
substitution at doses of 2.5 mg/kg (86.79% DLR) mg/kg and 5.0 mg/kg (94.82% DLR),
however only 4 of 6 subjects responded at the 5.0 mg/kg dose of CLZ. Response rates
were found to be significantly different (F 6, 41 = 2.51, p < 0.05) from VEH control
response rates, however a Newman-Keuls post-hoc tests revealed that there were no
significant differences from VEH control response rate at any dose tested. Clozapine’s
ED50 = 0.94 mg/kg (95% C.I. = 0.61 – 1.46 mg/kg).
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Haloperidol Substitution Tests
Haloperidol was tested for NDMC substitution with doses of 0.025, 0.05, 0.1, 0.2,
and 0.4 mg/kg (Fig. 11). Haloperidol did not produce substitution for 10.0 mg/kg NDMC
at any dose tested, with the highest mean drug lever percentage being 39.97% DLR when
administered 0.05 mg/kg haloperidol. Response rates were significantly reduced (F 6, 34 =
37.07, p < 0.01) as compared to VEH control response rates at all doses tested.
Experiment 2
10.0 mg/kg NDMC Acquisition
Twelve subjects began 10.0 mg/kg NDMC discrimination training. One mouse
became ill during training and was removed from the study. Following 47 training
sessions, only 3 of 11 remaining subjects acquired the discriminative stimulus of 10.0
mg/kg NDMC in a mean of 23.3 sessions with a range of 17-30 (SEM 3.76), while 8 of 11
subjects failed to pass training criteria. Subjects were given a 21 day drug washout period
before beginning 2.5 mg/kg clozapine discrimination training.
2.5 mg/kg Clozapine Acquisition
After the training drug was changed to 2.5 mg/kg clozapine, the mice (N = 11)
passed training criteria (7 of 8 days passed criteria) in a mean of 20.0 (SEM 2.71) doublelever training sessions with a range of 8 to 33 sessions (Fig. 12). One subject was removed
from the study for failing to pass training criteria after 48 training sessions. Following 2.5
mg/kg clozapine acquisition, the mice completed VEH and CLZ control points and a CLZ
generalization curve.
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Clozapine Dose Effect Curve 1 (DEC 1)
Ten subjects began testing with CLZ doses of 0.3125, 0.625, 1.25, 2.5, and 5.0
mg/kg following completion of acceptable VEH and CLZ control points (> 80% DLR and
10.0 RPM). The dose response curve was completed with two training days (1 CLZ 1
VEH) in a counterbalanced order between each test dose and between subjects; the mice
were randomly assigned to complete dose tests in an ascending or descending order. The
clozapine dose of 1.25 mg/kg produced partial substitution (67.42% DLR), while 2.5
mg/kg (96.75% DLR) and 5.0 mg/kg (99.96% DLR) produced full substitution for 2.5
mg/kg CLZ (Fig. 13). Only 5 of 10 ten subjects responded at the 5.0 mg/kg dose of CLZ,
and response rates were significantly (F 6, 69 = 11.80, p < 0.01) different from VEH control
response rates at that dose as revealed by a Newman-Keuls post-hoc test. The other tested
doses of 0.3125 mg/kg (29.85% DLR), 0.625 mg/kg (49.26% DLR) did not produce
substitution for 2.5 mg/kg CLZ. The clozapine ED50 = 0.63 mg/kg (95% C.I. = 0.49 – 0.80
mg/kg) for Dose Effect Curve 1.
Clozapine Dose Effect Curve 2 (DEC 2)
The mice began DEC 2 following 10 consecutive days of 10.0 mg/kg NDMC
injections twice daily (9 AM and 6 PM). DEC 2 was completed without any training days
in between tests, and subjects were randomly assigned to test doses in ascending or
descending order. Subjects tested doses of 0.625, 1.25, 2.5, 5.0, and 10.0 mg/kg in 5
consecutive days (Fig. 14). The 10.0 mg/kg dose of CLZ fully substituted (86.96% DLR)
for the 2.5 mg/kg CLZ discriminative stimulus, however only 5 of 10 subjects responded
when administered 10.0 mg/kg, and response rates (mean = 13.36, SEM = 4.59) were
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significantly (F 4, 49 = 12.35, p < 0.01) lower than response rates for all other doses tested.
The CLZ doses of 0.625 mg/kg (28.25% DLR), 1.25 mg/kg (31.52% DLR), 2.5 mg/kg
(70.02% DLR), and 5.0 mg/kg (72.85% DLR) failed to fully substitute, however 2.5 mg/kg
and 5.0 mg/kg NDMC produced partial substitution. The CLZ ED50 = 1.89 mg/kg (95%
C.I. = 1.21 – 2.96 mg/kg) for DEC 2. Thus, there was a significant (p <0.05) right-ward
shift for the CLZ DEC 2 as compared to DEC 1 as there was no overlap in the confidence
intervals. Linear regression analysis revealed that the slopes of DEC 1 and DEC 2 were not
significantly different (F 1, 6 = 0.63, p = 0.46); however, the y-intercepts of DEC 1 and
DEC 2 were significantly different (F 1, 7 = 27.75, p < 0.01) from each other (Fig. 15).
Clozapine Dose Effect Curve 3 (DEC 3)
The mice began DEC 3 following 10 days of suspended training and no drug
administration. DEC 3 was completed exactly in the same manner as DEC 1, and
individual subjects were tested in the same dose order (ascending or descending) as they
were in DEC 1. As shown in Fig. 16, subjects were tested with doses of 0.3125, 0.625,
1.25, 2.5, and 5.0 mg/kg, and all subjects were tested with 10.0 mg/kg CLZ upon
completion of the other doses. Doses of 2.5 mg/kg (98.04% DLR) and 5.0 mg/kg (98.45%
DLR) fully substituted for the discriminative stimulus associated with 2.5 mg/kg CLZ.
None of the other tested doses substituted for 2.5 mg/kg CLZ, with the highest DLR
reported at 47.47 % at the 1.25 mg/kg dose. The CLZ ED50 = 0.77 mg/kg (95% C.I. = 0.52
– 1.13 mg/kg) for DEC 3; thus, there was a significant left-ward shift for the DEC 3 curve
as compared to DEC 2 and there was no overlap of the confidence intervals. Linear
regression analysis revealed that the slopes of DEC 2 and DEC 3 were not significantly
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different (F 1, 6 = 0.54, p = 0.49) from each other; however, the y-intercepts of DEC 2 and
DEC 3 were significantly different (F 1, 7 = 9.75, p < 0.05) from each other (Fig. 17). DEC
3 and DEC 1 were not significantly different from each other (Fig. 18) as ED50 values and
95% confidence intervals for DEC 3 and DEC overlapped. Linear regression analysis
revealed that the slopes of DEC 1 and DEC 3 were not significantly different (F 1, 6 = 0.03,
p = 0.86) from each other; the y-intercepts of DEC 1 and DEC 3 were also not significantly
different (F 1, 7 = 0.82, p = 0.40) from each other. The three dose-effect curves (DEC 1,
DEC 2, and DEC 3) are displayed in Fig. 19, showing the right-ward shift following
NDMC administration during DEC 2, and the left-ward shift of the DEC 3 curve following
the 10 days of drug washout.
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Figure 1. Acquisition of 2.5 mg/kg N-desmethylclozapine Discrimination
Figure 1. Acquisition of two-lever 2.5 mg/kg discrimination training criteria is shown. The
mean percentage drug lever responding (+ SEM) is shown for NDMC (filled circles) and
VEH (open circles) two-lever training sessions. The area above the dashed line at 80%
indicates group mean 2.5 mg/kg NDMC appropriate responding. As subjects passed
training criteria (5 of 6 sessions) they were removed from the acquisition curve, which was
indicated by decreasing N, shown in parenthesis.
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Figure 2. Acquisition of 5.0 mg/kg N-Desmethylclozapine Discrimination
Figure 2. Acquisition of two-lever 5.0 mg/kg NDMC discrimination training is shown. The
mean percentage drug lever responding (+ SEM) is shown for NDMC (filled circles) and
VEH (open circles) two-lever training sessions. The area above the dashed line at 80%
indicates group mean 2.5 mg/kg NDMC appropriate responding. As subjects passed
training criteria (5 of 6 sessions) they were removed from the acquisition curve, which was
indicated by decreasing N, shown in parenthesis.
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Figure 3. 5.0 mg/kg N-Desmethylclozapine Generalization Data
Figure 3. Generalization data for 5.0 mg/kg NDMC-trained mice is shown including mean
drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to the left y-axis
and mean response rate, shown as responses per minute (+ SEM) (open circles) plotted to
the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that fall above the
dashed line at 80% DLR are considered to fully substitute for the training drug/dose.
Control points were tested prior to testing other doses to confirm stimulus control.
Subjects’ percentage drug lever responding data was omitted from analysis if individual
response rate was less than 2.0 responses per minute. Significant decreases in response rate
are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 4. 5.0 mg/kg NDMC Generalization Data VEH Training Prior to Test
Figure 4. Generalization data for 5.0 mg/kg NDMC-trained mice including doses of 2.5,
5.0 and 10.0 mg/kg NDMC tested when VEH training session was conducted prior to test
session including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles)
plotted to the left y-axis and mean response rate, shown as responses per minute (+ SEM)
(open circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (%
DLR) that fall above the dashed line at 80% DLR are considered to fully substitute for the
training drug/dose. Subjects’ percentage drug lever responding data was omitted from
analysis if individual response rate was less than 2.0 responses per minute. Significant
decreases in response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 5. 5.0 mg/kg NDMC Generalization Data NDMC Training Prior to Test
Figure 5. Generalization data for 5.0 mg/kg NDMC-trained mice including doses of 2.5,
5.0 and 10.0 mg/kg NDMC tested when NDMC training session was conducted prior to
test session including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles)
plotted to the left y-axis and mean response rate, shown as responses per minute (+ SEM)
(open circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (%
DLR) that fall above the dashed line at 80% DLR are considered to fully substitute for the
training drug/dose. Subjects’ percentage drug lever responding data was omitted from
analysis if individual response rate was less than 2.0 responses per minute. Significant
decreases in response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 6. Aquistion of 10.0 mg/kg N-desmethylclozapine Discrimination
Figure 6. Acquisition of two-lever 10.0 mg/kg NDMC discrimination training criteria is
shown. The mean percentage drug lever responding (+ SEM) is shown for NDMC (filled
circles) and VEH (open circles) two-lever training sessions. The area above the dashed
line at 80% indicates group mean 10.0 mg/kg NDMC appropriate responding. As subjects
passed training criteria (7 of 8 sessions) they were removed from the acquisition curve,
which was indicated by decreasing N, shown in parenthesis.
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Figure 7. 10.0 mg/kg N-desmethylclozapine Generalization Data
Figure 7. Generalization data for 10.0 mg/kg NDMC-trained mice is shown including
mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to the left yaxis and mean response rate, shown as responses per minute (+ SEM) (open circles)
plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that fall
above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Control points were tested prior to testing other doses to confirm stimulus
control. Subjects’ percentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute. Significant decreases in
response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 8. 10.0 mg/kg NDMC Generalization Data VEH Training Prior to Test
Figure 8. Generalization data for 10.0 mg/kg NDMC-trained mice including doses of 10.0
and 20.0 mg/kg NDMC tested when VEH training session was conducted prior to test
session including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles)
plotted to the left y-axis and mean response rate, shown as responses per minute (+ SEM)
(open circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (%
DLR) that fall above the dashed line at 80% DLR are considered to fully substitute for the
training drug/dose. Subjects’ percentage drug lever responding data was omitted from
analysis if individual response rate was less than 2.0 responses per minute. Significant
decreases in response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 9. 10.0 mg/kg NDMC Generalization Data NDMC Training Prior to Test
Figure 9. Generalization data for 10.0 mg/kg NDMC-trained mice including doses of 10.0
and 20.0 mg/kg NDMC tested when NDMC training session was conducted prior to test
session including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles)
plotted to the left y-axis and mean response rate, shown as responses per minute (+ SEM)
(open circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (%
DLR) that fall above the dashed line at 80% DLR are considered to fully substitute for the
training drug/dose. Subjects’ percentage drug lever responding data was omitted from
analysis if individual response rate was less than 2.0 responses per minute. Significant
decreases in response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 10. Clozapine Substitution Data for 10.0 mg/kg NDMC-Trained Mice
Figure 10. Clozapine substitution data in 10.0 mg/kg NDMC-trained mice is shown
including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to
the left y-axis and mean response rate, shown as responses per minute (+ SEM) (open
circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that
fall above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Subjects’ percentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute, which was indicated by
noting the number of subjects to complete a particular data point in parenthesis next to that
data point. Significant decreases in response rate are noted by asterisks (* p < 0.05, ** p <
.01).
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Figure 11. Haloperidol Substitution Data for 10.0 mg/kg NDMC-Trained Mice
Figure 11. Haloperidol substitution data in 10.0 mg/kg NDMC-trained mice is shown
including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to
the left y-axis and mean response rate, shown as responses per minute (+ SEM) (open
circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that
fall above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Subjects’ spercentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute, which was indicated by
noting the number of subjects to complete a particular data point in parenthesis next to that
data point. Significant decreases in response rate are noted by asterisks (* p < 0.05, ** p <
.01).
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Figure 12. Acquisition of 2.5 mg/kg Clozapine Discrimination
Figure 12. Acquisition of two-lever 2.5 mg/kg discrimination training criteria is shown.
The mean percentage drug lever responding (+ SEM) is shown for NDMC (filled circles)
and VEH (open circles) two-lever training sessions. The area above the dashed line at 80%
indicates group mean 2.5 mg/kg NDMC appropriate responding. As subjects passed
training criteria (7 of 8 sessions) they were removed from the acquisition curve, which was
indicated by decreasing N, shown in parenthesis.

58

DEC 1
60

100

(5)

80

50
40

60

30

40
20

% DLR
RSP/MIN

0
CLZ VEH

.3125

.625

1.25

2.5

**

20
10
0

Responses Per Minute

%Drug Lever Responding

2.5 mg/kg Clozapine-Trained Mice (N=10)

5.0

Clozapine Dose (mg/kg)
Figure 13. 2.5 mg/kg Clozapine Generalization Data: DEC 1
Figure 13. Generalization data (DEC 1) for 2.5 mg/kg clozapine-trained mice is shown
including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to
the left y-axis and mean response rate, shown as responses per minute (+ SEM) (open
circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that
fall above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Control points were tested prior to testing other doses to confirm stimulus
control. Subjects’ percentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute. Significant decreases in
response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 14. 2.5 mg/kg Clozapine Generalization Data: DEC 2
Figure 14. Generalization data (DEC 2) for 2.5 mg/kg clozapine-trained mice is shown
including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted to
the left y-axis and mean response rate, shown as responses per minute (+ SEM) (open
circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that
fall above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Subjects’ percentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute. Significant decreases in
response rate are noted by asterisks (* p < 0.05, ** p < .01).
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Figure 15. 2.5 mg/kg CLZ DEC 1 and DEC 2 With Regression Lines
Figure 15. Generalization data (DEC 1 and DEC 2) for 2.5 mg/kg clozapine-trained mice
is shown including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles)
plotted to the y-axis and dose is plotted on the X axis. Data points (% DLR) that fall above
the dashed line at 80% DLR are considered to fully substitute for the training drug/dose.
Subjects’ percentage drug lever responding data was omitted from analysis if individual
response rate was less than 2.0 responses per minute. Linear regression revealed that the
slopes between the lines were not significantly different. The elevations of the lines
however, were found to be significantly different indicating a significant right-ward shift
of the dose-response curve in DEC 2.
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Figure 16. 2.5 mg/kg Clozapine Generalization Data: DEC 3
Figure 16. Generalization data (DEC 3) for 2.5 mg/kg clozapine-trained mice is shown
including mean drug lever percentage choice (% DLR) (+ SEM) (filled circles) plotted on
the left y-axis and mean response rate, shown as responses per minute (+ SEM) (open
circles) plotted to the right y-axis. Dose is plotted on the X axis. Data points (% DLR) that
fall above the dashed line at 80% DLR are considered to fully substitute for the training
drug/dose. Subjects’ percentage drug lever responding data was omitted from analysis if
individual response rate was less than 2.0 responses per minute. Significant decreases in
response rate are noted by asterisks (* p < 0.05, ** p < .01).

62

%Drug Lever Responding

2.5 mg/kg Clozapine-Trained Mice
DEC 2 (N=10) and DEC 3 (N=9)
(7)

100
80

(5)

60
40
20

DEC 2
DEC 3

0
0

.3125

.625

1.25

2.5

5.0

10.0

Clozapine Dose (mg/kg)
Figure 17. 2.5 mg/kg CLZ DEC 2 and DEC 3 With Regression Lines
Figure 17. Generalization data (DEC 1 and DEC 2) for 2.5 mg/kg clozapine-trained mice
is shown including mean drug lever percentage choice (% DLR) (+ SEM) plotted on the yaxis and dose is plotted on the X axis. Data points (% DLR) that fall above the dashed line
at 80% DLR are considered to fully substitute for the training drug/dose. Subjects’
percentage drug lever responding data was omitted from analysis if individual response
rate was less than 2.0 responses per minute. Linear regression revealed that the slopes
between the lines were not significantly different. The elevations of the lines however,
were found to be significantly different indicating a significant right-ward shift of the doseresponse curve in DEC 2.
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Figure 18. 2.5 mg/kg CLZ DEC 1 and DEC 3 With Regression Lines
Figure 18. Generalization data (DEC 1 and DEC 3) for 2.5 mg/kg clozapine-trained mice
is shown including mean drug lever percentage choice (% DLR) (+ SEM) plotted on the yaxis and dose is plotted on the X axis. Data points (% DLR) that fall above the dashed line
at 80% DLR are considered to fully substitute for the training drug/dose. Subjects’
percentage drug lever responding data was omitted from analysis if individual response
rate was less than 2.0 responses per minute. Linear regression revealed that the slopes
between the lines were not significantly different. The elevations of the lines were also not
significantly different indicating a significant right-ward shift of the dose-response curve in
DEC 2.
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Figure 19. 2.5 mg/kg CLZ DEC 1, DEC 2 and DEC 3 With Regression Lines
Figure 19. Generalization data (DEC 1 DEC 2, and DEC 3) for 2.5 mg/kg clozapinetrained mice is shown including mean drug lever percentage choice (% DLR) plotted on
the y-axis and dose is plotted on the X axis. Data points (% DLR) that fall above the
dashed line at 80% DLR are considered to fully substitute for the training drug/dose.
Subjects’ percentage drug lever responding data was omitted from analysis if individual
response rate was less than 2.0 responses per minute. Linear regression revealed that the
slopes between the lines were not significantly different. The elevations of the lines were
also not significantly different indicating a significant right-ward shift of the dose-response
curve in DEC 2.
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Discussion
The present study set out to examine the discriminative stimulus properties of Ndesmethylclozapine in C57BL/6 mice, by establishing NDMC as a discriminative stimulus
using a two-lever operant procedure, and to evaluate substitution tests of other
antipsychotic compounds. To our knowledge, N-desmethylclozapine has not been
established as a discriminative stimulus in any species of animal. We chose to establish
this stimulus in mice in order to compare results with clozapine-trained mice, and to
provide the possibility of studying transgenic and knockout mice in the future. Ndesmethylclozapine does not substitute for clozapine in CLZ-trained mice (Prus et al.,
2008; Philibin et al., 2009), so our first question to ask after establishing NDMC as a
discriminative stimulus was whether or not CLZ will substitute for its major active
metabolite, NDMC. Following that assessment the mice were tested with haloperidol and
aripiprazole.
Experiment 1
Subjects began drug discrimination training with a 2.5 mg/kg dose of NDMC.
Following 57 double-lever training sessions only 5 of 12 subjects had met the training
criteria set forth for drug discrimination. The first training dose used had been based on the
training dose previously used with the parent drug clozapine (2.5 mg/kg) and also the
lowest dose tested for CLZ substitution used in studies assessing the same strain of mouse
(Philibin et al., 2009). Philibin and colleagues found that 2.5 mg/kg NDMC failed to
substitute for CLZ and also failed to produce significant rate suppression (2009).
Following 57 training sessions with less than half of subjects meeting criteria in the present
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study, it became obvious that 2.5 mg/kg NDMC was not readily discriminated by C57BL/6
mice. Inspection of the data in Figure 1 suggests that subjects were discriminating NDMC
after roughly 22 sessions, but Figure 1, and other acquisition figures in the paper display
percent drug lever responding, which was only one of three training criteria that must be
passed before testing can begin. The criterion that was most often missed by subjects was
the first fixed ratio (FFR) of the session. The mice readily learned to switch levers after
completing a ratio, in this case FR 10, which was not reinforced with sweetened milk.
Thus, mice rarely missed total lever percentage, or had response rates of less than 10.0
responses per minute after habituating to the procedure of drug discrimination training.
The acquisition of 5.0 mg/kg NDMC was much more rapid and successful, as all 9
remaining subjects in the study acquired the discriminative stimulus in a mean of 15.7
double-lever training sessions with a range of 6 to 29 sessions as shown in Figure 2. The
data shown in Figure 2 show that the subjects were discriminating based on overall DLR
percentage and appropriate response rates on session 1, but again, FFR was the limiting
criteria to begin substitution testing.
Following acquisition of discrimination training with 5.0 mg/kg NDMC a dose
effect curve was generated as shown in Figure 3. The data produced for the NDMC
generalization curve looked normal until animals were tested with the 5.0 mg/kg training
dose and the 10.0 mg/kg dose of NDMC. The mice failed to show full or partial
substitution (50.49% DLR) with 5.0 mg/kg NDMC, which was the training dose, and 10.0
mg/kg NDMC only produced partial substitution (75.13% DLR). This revealed a fading or
loss of the discriminative stimulus over time. Subjects were tested with doses of 2.5, 5.0,
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and 10.0 mg/kg NDMC with either a NDMC or VEH training session the day prior to
testing (the opposite condition to which each subject had been tested on before). When the
results were plotted as a function of the training condition (see Figure 4), it was found that
the mice failed to substitute at doses of 2.5 mg/kg (35.5% DLR) and 5.0 mg/kg (41.33%
DLR) NDMC and only showed partial substitution (67.07% DLR) with 10.0 mg/kg
NDMC when a VEH training session preceded the test session. Subjects fully substituted
with all three doses tested (93.03%, 84.22%, and 95.01% respectively) when a NDMC
training session immediately preceded the test session (see Figure 5). This indicated that
5.0 mg/kg NDMC was not serving as an effective discriminative stimulus.
Thus, the training dose of NDMC was increased to 10.0 mg/kg after subjects failed
to retain discrimination of the 5.0 mg/kg NDMC training dose. The training criteria were
also changed, as subjects were required to pass all 3 criteria for 7 of 8 consecutive doublelever training sessions before beginning testing. Also, after beginning testing, subjects
were required to pass both a VEH and a NDMC training session consecutively
immediately prior to testing in order to ensure that the animals were maintaining stimulus
control. The higher dose of 10.0 mg/kg NDMC was able to be successfully trained in a
mean of 27.5 sessions with a range of 14 to 58 sessions (Fig. 6). The dose effect curve
revealed that both 10.0 and 20.0 mg/kg NDMC fully substituted for the training dose
(83.95% and 86.92% DLR respectively) without producing significant rate suppression as
shown in Figure 6. This generalization profile was different from that of clozapine, as CLZ
produced significant rate suppression at 1 log2 step above the training dose.
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After completion of the NDMC dose effect curve, subjects were re-tested with the
highest doses of the curve, 10.0 and 20.0 mg/kg, but again with the opposite preceding
training condition to which they had been tested on before. It revealed that 10.0 mg/kg
NDMC failed to fully substitute with VEH training prior to testing (62.66% DLR) and with
NDMC training prior to testing (73.16% DLR) as shown in Figure 7. The highest dose
tested of 20.0 mg/kg NDMC fully substituted under both conditions (84.26% and 98.23%
respectively) as shown in Figure 8. This observation revealed that there still may be a
tolerance or fading problem developing with the discriminative stimulus training dose of
10.0 mg/kg NDMC. It also suggests that NDMC has a weak discriminative stimulus
overall, and is difficult to establish as a training drug. This shifting discriminative stimulus
or loss of discrimination over time indicated that NDMC may be difficult to study using
drug discrimination. It requires precautions to be taken including implementing stringent
training and testing criteria to ensure good stimulus control.
The first compound tested for substitution was the parent drug of Ndesmethylclozapine, clozapine, as NDMC did not substitute in CLZ-trained mice (Philibin
et al., 2009). We expected that CLZ might substitute in 10.0 mg/kg NDMC trained-mice
even though NDMC itself didn’t substitute for CLZ in C57BL/6 mice, as a combination
dose of 0.625 mg/kg CLZ plus 10.0 mg/kg NDMC fully substituted for CLZ, although it
also significantly reduced response rates (Philibin et al., 2009). A combination dose of
CLZ (0.3125 mg/kg) plus NDMC (5.0 or 10.0 mg/kg) also substituted for CLZ in 1.25
mg/kg CLZ-trained rats, and the 5.0 mg/kg dose combined with the 0.3125 dose of CLZ
fully substituted without producing significant rate suppression (Prus et al., 2009). In the
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present study, clozapine was found to fully substitute (86.79% and 94.82% DLR) at the
two highest doses (2.5 and 5.0 mg/kg) tested, and interestingly, both doses that fully
substituted failed to produce a significant reduction in response rate as compared to VEH
control response rates as shown in Figure 9. Even though, 5.0 mg/kg did not produce a
significant reduction of response rates, 2 of the 6 subjects tested failed to respond when
given 5.0 mg/kg, which is a common effect seen in 2.5 mg/kg CLZ-trained mice when
tested with a 5.0 mg/kg dose. The subjects that responded produced such a high response
rate that the mean produced was not significantly different from the VEH control response
rate. Because the response rates of subjects that responded were so high, it suggested that
NDMC may play a role in providing protection from CLZ’s rate-reducing effects at doses
higher than the training dose. This generalization of the NDMC discriminative stimulus to
CLZ, along with lack of CLZ generalization to NDMC displays an asymmetrical
generalization between the two compounds, which has been found in other drug
discrimination studies including studies of MDMA and cocaine, ephedrine and
methamphetamine, and alcohol and NMDA antagonists, (Bondareva, Young, & Glennon,
2002; Khorana, Pullagurla, Young, & Glennon, 2003; Bondareva, Wesoloska, Dukat, Lee,
Young, & Glennon, 2005; Butelman, Baron, & Woods, 1993) .
It was interesting that clozapine was found to fully substitute for its metabolite,
NDMC, given that NDMC didn’t substitute for CLZ at any dose in past studies; however,
this was somewhat expected because CLZ is rapidly metabolized to NDMC, therefore it
may be an important component of CLZ’s discriminative stimulus. This asymmetrical
generalization is most likely due to differences in receptor activity at M1 muscarinic and/or
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D2 dopaminergic receptors. A study by Prus and colleagues has shown that NDMC
administered in combination with trihexyphenidyl, an M1 receptor agonist, full clozapine
substitution was produced, although it was accompanied by significant rate-suppression
(Prus et al., 2008). This shows M1 antagonism may play a role in CLZ’s discriminative
stimulus, although this has only been shown in rats, not mice (Philibin 2005; 2009). It
makes sense that CLZ will substitute for NDMC as CLZ is rapidly metabolized to NDMC
in the mouse and may possibly contribute to substitution for the NDMC discriminative
stimulus. NDMC and CLZ also show difference at D2 receptors, with NDMC being a
partial agonist, and CLZ a D2 antagonist, but since CLZ is metabolized into NDMC after
administration, it makes sense that CLZ substitutes for NDMC.
Haloperidol failed to substitute for NDMC at any dose tested (0.025, 0.05, 0.1, 0.2,
and 0.4 mg/kg), but significant response rate reductions were observed at all doses as
compared to VEH response rates. A visual analysis of Figure 10 reveals that the VEH
response rate was the highest observed in any dose effect or generalization curve generated
in the present study. The two highest doses of haloperidol (0.2 and 0.4 mg/kg) appeared to
reduce response rates markedly more than the lower doses. This confirms past research
from our lab and others that show typical APDs such as haloperidol fail to substitute for
the atypical APD, CLZ (Goas & Boston, 1978; Porter et al., 2000; Porter et al., 2008 &
Goudie et al., 1998).
After some training dose adjustments NDMC was able to be trained and maintained
as a discriminative stimulus, although continuous assessment of stimulus control was
required in order to properly conduct substitution tests in subjects. Generation of the dose-
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effect curve revealed a dose-dependent relationship for NDMC and drug lever response
percentage, which is important when assessing drugs as discriminative stimuli. It is
important to establish NDMC as a discriminative stimulus, as it has been found to
contribute to the clinical efficacy of CLZ, and its properties need to be further investigated
(Flanagan et al., 2003). NDMC may also be important for cognition, as patients with
higher ratios of NDMC to CLZ show more cognitive improvement (Weiner et al., 2004).
Understanding the similarities and differences between CLZ and NDMC in vivo may lead
investigators to develop new strategies in clinical treatment. Establishing NDMC as a
discriminative stimulus also provides further evidence that it is behaviorally active in the
brain, as shown by studies assessing Fos protein expression in the prefrontal cortex of rats
and by studies showing NDMC’s ability to reverse both MK-801 and amphetamine
induced hyperactivity which is a preclinical model of psychotic behavior that can be
reversed by APDs (Young et al., 1998; see Lameh et al., 2007).
Experiment 2
In Experiment 1, it was observed that during CLZ substitution testing there
appeared to be some tolerance development to the rate-suppressing effects of CLZ; thus it
was hypothesized that there might be a cross-tolerance between CLZ and its major
metabolite N-desmethylclozapine. To assess this possible cross-tolerance, a method similar
to that of a pair of studies conducted by Goudie and colleagues was employed (Goudie et
al., 2007a; Goudie et al., 2007b). A group of mice (N = 11) was trained to discriminate 2.5
mg/kg CLZ from VEH and a CLZ dose effect curve was determined. Following this first
dose effect curve (DEC 1), the subjects were administered 10.0 mg/kg NDMC twice daily
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for 10 days. A second CLZ dose response curve was generated following 10 days of
repeated NDMC administration. The regression lines for the two dose response curves
remained parallel, but there was a significant right-ward shift in the dose response curve
indicating the development of cross-tolerance between NDMC and CLZ (Fig 15).
In Experiment 2 subjects were first trained with 10.0 mg/kg NDMC using methods
similar methods to those used in Experiment 1 when 10.0 mg/kg NDMC was trained as a
discriminative stimulus. In Experiment 1, the subjects that achieved training criteria for
10.0 mg/kg NDMC had an extensive, and complicated training history that involved
increasing the training dose 3 times throughout the course of the experiment. This training
history may have impacted training of the 10.0 mg/kg NDMC dose and subsequent
substitution tests (Stolerman & White, 1996). In Experiment 2, subjects had no training or
drug history before beginning 10.0 mg/kg NDMC training. Drug-naïve mice were used in
order to determine if training history affected the acquisition of 10.0 mg/kg NDMC
discrimination in Experiment 1. The majority of the mice (8 of 11) were unable to pass the
discrimination training criteria after 57 training sessions. The three subjects that were able
to pass the criteria did so in a mean of 23.3 double-lever training sessions with a range of
17 to 30 sessions.
Since only 3 subjects were able to discriminate 10.0 mg/kg NDMC from VEH
reliably, NDMC discrimination training was suspended and the mice were given 14 days
of free access to food followed by 7 days to re-establish food deprivation before training to
discriminate 2.5 mg/kg clozapine from VEH began. The acquisition of the training criteria
for 2.5 mg/kg CLZ discrimination, shown in Figure 11, was similar to that displayed in
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Figure 2 for 5.0 mg/kg NDMC. The acquisition curve is flat due to the past training history
of discrimination training with 10.0 mg/kg NDMC. As discussed earlier, the subjects were
easily able to pass 2 of the 3 criteria at the beginning of discrimination training, but failure
to pass the FFR criterion was the most common criteria to miss. All 11 subjects passed the
training criteria in a mean of 20.0 double-lever training sessions, with a range of 8 to 33
sessions. The only change made to the discrimination training procedure was that subjects
were trained or tested 7 days a week for the entire experiment. This minimized variability
on test and training days and maintained a high level of stimulus control over the 2.5
mg/kg CLZ discriminative stimulus.
The dose effect curve generated initially (DEC 1) produced an ED50 for CLZ dose
that was not found to be significantly different than another group of C57BL/6 mice being
currently trained in another project (Philibin et al., 2005). DEC 1 shows full substitution
with doses of 2.5 and 5.0 mg/kg CLZ for the training dose of 2.5 mg/kg CLZ; however,
there was significant response rate reduction as compared to VEH response rates at the 5.0
mg/kg dose. Only 5 of the 11 subjects responded at that dose, which was comparable to
past data from our lab. This provides support that the CLZ discrimination acquisition was
not hindered by the behavioral history of 10.0 mg/kg NDMC training. Upon completion of
DEC 1, the mice were given 10 days of 10.0 mg/kg NDMC injections twice daily.
DEC 2 was generated immediately following the 10 days of 10.0 mg/kg NDMC
administration. The dose effect curve was also generated with no training days in between
tests, to prevent the loss of any tolerance induced by NDMC administration; this was a
replication of Goudie’s DEC 2 as it was thought that it was more important to preserve the
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tolerance that may have developed over the 10 days of dosing than assessing stimulus
control, as that would be assessed in the final dose effect curve (DEC 3). The lowest dose
(0.3125 mg/kg) of CLZ was not tested in DEC 2, to minimize chances of losing tolerance
during testing, similar to Goudie’s methods, which did not test the lowest dose in the curve
following repeated drug administrations (DEC 2). The first subject was tested with doses
of CLZ in an ascending order and 5.0 mg/kg CLZ failed to produce substitution for the
training dose of 2.5 mg/kg CLZ, and also failed to significantly reduce response rates.
Following this observation, a high dose of 10.0 mg/kg CLZ was also tested in all subjects
to assess its ability to produce 2.5 mg/kg CLZ substitution. The ED50 generated from the
DEC 2 data was found to be significantly different than the DEC 1 ED50 and the doseeffect curve was significantly shifted right-ward, indicating tolerance, or lessening of the
discriminative stimulus. The tolerance was shown for both DLR percentage and in
response rate suppression. During DEC 1, 5.0 mg/kg CLZ produced significant response
rate suppression, which was not seen in DEC 2; however, 10.0 mg/kg CLZ produced
significant rate suppression in DEC 2.
Following DEC 2, training was suspended for 10 consecutive days without drug
treatment. On day 11, subjects were trained for 2 days including both a CLZ and VEH
training condition, and then completed the final dose-effect curve (DEC 3). DEC 3 was
conducted exactly as DEC 1 for each individual subject; each test was separated by 2
training days, and subjects were assigned to ascending or descending dose test order based
on the order tested during DEC 1. The ED50 completed during DEC 3 was not significantly
different from the ED50 calculated for DEC 1; however, it was significantly different from
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the ED50 calculated for DEC 2, showing a significant left-ward shift for DEC 3 as
compared to DEC 2. This significant shift was confirmed using linear regression analysis,
indicating a loss of the tolerance displayed in DEC 2.
Thus, N-desmethylclozapine induced cross-tolerance to clozapine’s discriminative
stimulus, suggesting that NDMC’s discriminative stimulus properties share some
similarities to its parent drug CLZ. However, despite this ability to produce cross-tolerance
to CLZ’s discriminative stimulus, NDMC does not substitute for CLZ in mice or rats
trained to discriminate CLZ from VEH at any dose tested, despite producing significant
rate suppression (Philibin et al., 2009; Prus et al., 2009). CLZ substituted for NDMC in
mice that were trained to discriminate NDMC from VEH in the present study. These
results support findings from in vitro studies suggesting that NDMC and CLZ show many
similarities in their receptor binding, but with a couple of important differences at M1
muscarinic and D2 dopamine receptors (Lameh et al., 2007).
Assessing the induction of cross-tolerance to clozapine is important, because APDs
are almost always administered repeatedly over time, rather than given only acutely; In
addition to that, therapeutic effects produced by administration of CLZ are usually not
apparent until after repeated use of CLZ. This indicates that long-term receptor based or
metabolic changes may take place during CLZ treatment that contribute to or create the
therapeutic effects seen in patients using clozapine. Since long-term administration is the
typical situation encountered by patients prescribed CLZ, it is important that we assess the
preclinical effects of CLZ after repeated administration as well. One way to examine
effects of a given drug over time is to examine its effects on generalization of a
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discriminative stimulus. Cross-tolerance assessment can be used to examine similarities in
drugs administered over long periods of time, and one way to assess cross-tolerance to
CLZ is to examine effects of repeated administration of a drug to a subject who is trained
to discriminate CLZ from VEH. If repeated administrations of a certain drug produce a
right-ward shift in the dose-response curve, it indicates cross-tolerance development. The
current study displayed cross-tolerance development both through a significant right-ward
shift in the dose-response curve, and also potentiation of previously suppressed response
rates. This indicates that possible neuroadaptive or metabolic changes take place during
NDMC administration, which are similar to those shown during CLZ administration.
Goudie and colleagues have shown that cross-tolerance induction to a
discriminative stimulus is relatively pharmacologically specific, as JL13, olanzapine, and
clozapine all induce cross-tolerance to the CLZ discriminative stimulus, but
chlordiazepoxide failed to induce tolerance (Goudie et al., 2007a & Goudie et al., 2007b).
However, this also points to the fact that drugs with similar receptor mechanisms to CLZ
may induce cross-tolerance to the discriminative stimulus, but still fail to possess any
antipsychotic efficacy in the clinic, such as cyproheptadine, which lacks D2 binding
affinity. It is important to interpret results cautiously given the fact that cyproheptadine
produces a false positive in terms of screening for APDs using this cross-tolerance
development procedure; however, it may still be used to test for pharmacological
similarities of drugs.
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Future Studies
We are currently testing aripiprazole for substitution in 10.0 mg/kg NDMC-trained
mice. Due to its similarity in D2 dopamine receptor activity, aripiprazole may have similar
discriminative stimulus properties to NDMC, indicating the importance of D2 partial
agonism in the discriminative stimuli of both compounds. Substitution of aripiprazole for
NDMC may indicate that NDMC should be further investigated as a potential APD as
aripiprazole was recently approved by the FDA for treatment of schizophrenia, and is the
first APD to have D2 partial agonism. We are also currently training aripiprazole as a
discriminative stimulus in C57BL/6 mice in order to further investigate the discriminative
stimulus properties of aripiprazole. After testing clozapine and haloperidol for substitution,
NDMC will be assessed in the assay. The generalization results between these two studies
will help to determine how similar the two compounds are, and specific differences can be
assessed be using selective agonists and antagonists to separate mechanisms mediating the
discriminative stimuli. Future studies assessing the discriminative stimulus of NDMC
using selective agonists and antagonists would be helpful to discern the specific
differences between the discriminative stimuli of N-desmethylclozapine and clozapine.
Conclusion
Drug Discrimination is a useful preclinical model used to assess drug receptor
activity in vivo. Clozapine drug discrimination has been an important tool to discern
similarities and differences among various APDs in terms of receptor activation.
Establishing NDMC, CLZ’s major metabolite, as a discriminative stimulus will help define
the mechanistic differences between the two compounds. These studies may help the
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development of novel APDs with therapeutic effects similar to CLZ but with fewer
undesirable side-effects. Assessment of cross-tolerance development is also a method to
compare discriminative stimulus effects of different drugs, which utilizes longer term
administration of a drug to more accurately portray human APD use.
Although NDMC is clearly similar to CLZ in many ways, and is important for the
clinical effects of clozapine, it is not exactly the same as CLZ, and does not have the
clinical efficacy of its parent drug either. N-desmethylclozapine has recently endured some
negative results in phase II clinical trials indicating it may lack antipsychotic efficacy as a
stand-alone drug treatment for schizophrenia (Reuters, 2008). NDMC has shown promise
in some pre-clinical studies and is likely important for CLZ’s mechanism of action, so it is
still possible that NDMC may have some value as an “add on” to existing or forthcoming
treatments for schizophrenia due to its similar receptor binding profile to clozapine, and it
is still being investigated.
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